WO2013180526A1 - Skin regeneration and hair growth promoter containing edelweiss extract - Google Patents

Skin regeneration and hair growth promoter containing edelweiss extract Download PDF

Info

Publication number
WO2013180526A1
WO2013180526A1 PCT/KR2013/004833 KR2013004833W WO2013180526A1 WO 2013180526 A1 WO2013180526 A1 WO 2013180526A1 KR 2013004833 W KR2013004833 W KR 2013004833W WO 2013180526 A1 WO2013180526 A1 WO 2013180526A1
Authority
WO
WIPO (PCT)
Prior art keywords
edelweiss
extract
promoter
enzyme
hair
Prior art date
Application number
PCT/KR2013/004833
Other languages
French (fr)
Korean (ko)
Inventor
김수나
박필준
김아름
서정아
박원석
이영란
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Publication of WO2013180526A1 publication Critical patent/WO2013180526A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Definitions

  • the present invention relates to a skin regeneration and hair growth promoter comprising an edelweiss extract.
  • Hair loss can be classified into resting hair loss and growing hair loss according to the growth cycle, and the resting hair loss includes androgenetic alopecia caused by androgen, postpartum hair loss of women or endocrine disease, and rounded hair growth by circular growth. Hair loss, scar hair loss, or hair loss due to ringworm. In addition, hair loss is also known to occur due to local infection, endocrine disorders, genetic factors and autoimmunity.
  • Representative anti-hair loss agents currently include Propecia and Minoxidil, which are approved by the US FDA. These drugs have clinically definite effects, but also have side effects such as sexual dysfunction and skin irritation, and women can not use or use only in extremely limited amounts. Therefore, there is a growing interest in natural products formulations that can be safely used without any gender restrictions, but through a new mechanism so as not to have the above disadvantages.
  • the present invention seeks to provide a skin regeneration accelerator having an excellent skin regeneration promoting effect and a hair growth promoter having an excellent hair growth promoting effect.
  • One aspect of the present invention provides a skin regeneration accelerator and a hair growth promoter comprising an edelweiss extract as an active ingredient.
  • Another aspect of the present invention provides a cosmetic composition and a pharmaceutical composition comprising the accelerator.
  • the present invention also provides a skin regeneration accelerator comprising an extract of Edelweiss treated with cell wall degrading enzyme as an active ingredient.
  • the formulation according to the present invention may include an edelweiss extract as an active ingredient, thereby promoting Wnt / beta-catenin signal transduction, thereby exhibiting excellent skin regeneration effect, specifically excellent skin wound healing and scar reduction effect.
  • the preparation not only promotes wint / beta-catenin signal transduction, but also activates stem cells of the dermal papilla cells and promotes the proliferation of dermal papilla cells of the hair follicles, thereby exhibiting an excellent hair growth promoting effect, further preventing hair loss and promoting wool. have.
  • the accelerator including the extract of the enzyme-treated edelweiss according to the present invention can increase the extraction efficiency of the active ingredient in the plant cell, the content of chlorogenic acid is rapidly increased, and the antioxidant activity is increased with a high content of chlorogenic acid, By further promoting the transmission of Wnt / beta-catenin (Wnt / beta-catenin) signal can exhibit an improved skin regeneration effect, specifically excellent skin wound healing and scar reduction effect, hair growth promoting effect.
  • Figure 3 is a graph showing the hair follicle dermal papilla cell growth promoting effect of the edelweiss extract.
  • Figure 4 is a graph showing the hair growth promoting effect and the effect of maintaining the hair follicle growth period in the hair follicle of Edelweiss extract.
  • FIG. 5 is a graph showing that the enzyme-treated Edelweiss extract promotes Wnt / beta-catenin signal transduction of stem cells.
  • Figure 6 is a graph showing the hair follicle dermal papilla cell growth promoting effect of the enzyme treatment Edelweiss extract.
  • Figure 7 is a graph comparing the content of chlorogenic acid as an indicator component contained in the edelweiss extract and the enzyme treatment edelweiss extract.
  • Each tissue in the human body contains adult stem cells that produce the cells that make up that tissue.
  • the cells that make up skin or hair are also derived from stem cells present in the skin or hair follicles.
  • Stem cells generally refer to pluripotent cells that can develop into any tissue. It has the ability to self-renewal to regenerate itself and to differentiate into cells with specific functions depending on the environment. These stem cells can be roughly divided into embryonic stem cells (adryonic stem cells) and adult stem cells (adult stem cells).
  • Embryonic stem cells are derived from fertilized eggs produced by fertilization of sperm, a male germ cell and an egg, a female germ cell. It is also called pluripotent stem cell because it has the ability to differentiate into various cell types. Embryonic stem cells are capable of mass proliferation and differentiation into almost all body cells, and have no immune rejection reaction, so that they can be transplanted to other species as well as others. However, it is difficult to control differentiation, which may lead to cancer cells, requiring technical precision, and accompanied by destruction of the fertilized egg, which may be an ethical problem.
  • Adult stem cells generally refer to cells that differentiate into cells of specific tissues when needed, and usually only a small amount is present in each tissue of the body. That is, adult stem cells of bone marrow cells are differentiated into hematopoietic cells, skin adult stem cells into skin, and adult stem cells of olfactory neurons into olfactory neurons. These adult stem cells are stable and are unlikely to become cancer cells, and unlike embryonic stem cells, they do not destroy fertilized eggs, so it is not ethically problematic.
  • Hair follicle stem cells are adult stem cells that exist in the hair follicles and produce the cells that make up the skin and hair, which are derived from hair follicle stem cells and mesenchymal stem cells, which may be derived from epithelial cells, also called bulge stem cells.
  • the hair follicle dermal papilla cells and neural stem cells derived from melanin-forming stem cells can be largely divided into three types.
  • One aspect of the present invention provides a skin regeneration accelerator comprising an edelweiss extract as an active ingredient.
  • Another aspect of the present invention provides a hair growth promoter comprising an edelweiss extract as an active ingredient.
  • the edelweiss extract may be an enzyme-treated edelweiss extract.
  • the promoter may heal a skin wound.
  • the accelerator may prevent hair loss or promote wool.
  • the promoter may activate a Wnt signal.
  • Wnt / beta-catenin signaling is a signaling system involved in the development of living organisms and is known to act on skin formation and hair follicle development. Furthermore, when a wound occurs on the skin, it is known that wint signal transduction is essential during skin tissue recovery to promote differentiation of epithelial cells. Therefore, if the wint signal is promoted, the differentiation of epithelial cells may be promoted to promote skin regeneration, and further, the healing of skin wounds may be promoted.
  • the enzyme-treated edelweiss extract of the present disclosure promotes the transmission of Wnt / beta-catenin in stem cells. Therefore, the formulation containing the same may promote skin regeneration, and in particular, may promote healing of skin wounds.
  • the treatment of the winte protein in the mouse promotes hair growth, it has been known that hair growth is inhibited in mice knocked down the wint gene. This means that substances that promote wint / beta-catenin signal transduction present in hair follicle stem cells can promote hair growth. Since substances that promote hair growth through this mechanism are not involved in promoting hair growth through the regulation of testosterone and / or blood circulation, severe hair loss and which have not been addressed by methods of inhibiting testosterone or promoting blood circulation and Female hair loss can be improved.
  • the activity of the dermal papilla cells may be promoted to promote hair growth.
  • Edelweiss extract promotes Wnt / beta-catenin signaling in stem cells and activates stem cells in dermal papilla cells.
  • Edelweiss extract also promotes the growth of hair follicle dermal papilla cells. Therefore, the formulation containing the edelweiss extract can promote hair growth, further prevent hair loss and promote wool.
  • the hair growth accelerator including the edelweiss extract may have a superior hair growth promoting, hair loss prevention and wool promoting effect than minoxidil, which is known as a conventional hair growth promoter, has little side effects such as sexual dysfunction or skin irritation, and has no gender. Can be used regardless.
  • the edelweiss includes a plant of the genus Leontopoium sp. In one embodiment of the present invention, the edelweiss may be Leontopoium alpinum .
  • the "Edelweiss” may be a plant of the genus Leontopoium sp. Leontopoium sp. Plants are Leontopoium alpinum , Leontopodium andersonii , Leontopodium artemisiifolium , Leontopoium auran Tiacum ( Leontopodium aurantiacum ), Leontopodium brachyactis , Leontopodium calocephalum , Leontopodium campestre , Leontopoium chuii , Leontopodium chuii , Umm beans Rover lithium (Leontopodium conglobatum), Leon topoyi help Correa num (Leontopodium coreanum), Leon topoyi help Dedeman Ken City (Leontopodium dedekensii), Leon topoyi help to Surabaya yanum (Leontopodium delavayanum), with Leon topoyi help disco (Leontopodium discolor) Leon topoyi
  • Edelweiss Leontopoium alpinum
  • Campanula Asteraceae is an alpine plant that lives primarily in dry places. The leaves are relatively high in the roots, slightly on the stems, and linear. At the end of the stem, the squirrel gathers, spreads out all over it, with a slight heading in the middle.
  • edelweiss may be included in the form of an extract, or may be included as a ground powder of the herbal medicine, or as a dry ground powder of the herbal medicine, but is not limited thereto.
  • the edelweiss used in the present specification is not limited to the method of acquiring, can also be grown and used or purchased commercially available, can use some or all of the above-ground parts of the herb, preferably all of the above-ground parts can be used have.
  • extract includes all materials obtained by extracting the components of natural products, regardless of the extraction method, extraction solvent, extracted components or the form of the extract, and extracts the substances obtained by extracting the components of natural products. It is a broad concept that includes all of the materials that can be obtained by processing or processing in a method.
  • edelweiss extract includes all materials obtained by extracting the components of edelweis, regardless of the extraction method, the extraction solvent, the extracted components or the form of the extract, and heat, acid (acid) in the process of extracting the components.
  • Material obtained through the extraction method including the step of treating with a base, an enzyme, and the like, and a material obtained by extracting an edelweiss component and then processing or treating it by another method. All inclusive is a broad concept.
  • the edelweiss extract is a step of washing and drying the edelweiss; Solvent extraction of the dry edelweiss; And it can be obtained through the step of filtering the extracted edelweiss.
  • the solvent includes at least one selected from the group consisting of water, an organic solvent, and a mixture of water and an organic solvent.
  • water includes distilled water or purified water
  • the organic solvent is selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform, for example, a lower alcohol having 1 to 5 carbon atoms. Including but not limited to one or more.
  • the edelweiss extract may include an edelweiss-C 1 ⁇ C 6 alcohol extract, specifically, the alcohol may be methanol or ethanol.
  • the edelweiss extract may be a crude extract of water, a C 1 -C 6 alcohol, and a solvent selected from the group consisting of a combination thereof.
  • the C 1 -C 6 alcohol may be specifically methanol.
  • the extraction may be a heat extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction, and the like, there is no limitation if the extraction is obvious to those skilled in the art.
  • the extraction may be performed at room temperature, but for more efficient extraction, the extraction may be performed under heating conditions, preferably at about 40 to 100 ° C., more preferably at about 80 ° C., but is not limited thereto. It is not.
  • the extraction time is preferably about 2 to 4 hours, more preferably about 3 hours, but is not limited thereto, and may vary depending on conditions such as extraction solvent and extraction temperature.
  • the extraction may be extracted one or more times several times in order to obtain a larger amount of the active ingredient, preferably one to five times, more preferably three times the continuous extraction can be used combined extract.
  • the edelweiss extract may include the crude extract of edelweis as described above, and may include the crude extract as a soluble fraction of the organic solvent obtained by further extracting the organic extract with a low polarity organic solvent. Hexane, methylene chloride, ethyl acetate, n-butanol, and the like may be used as the organic solvent, but is not limited thereto.
  • the extract extracted by the above method or a soluble fraction of the extract may be used as it is, but may be used in the form of an extract by concentrating after filtration, it may be used as a lyophilized form by lyophilization after concentration.
  • skin refers to a tissue covering the body surface of an animal, and is a broad concept including not only tissues covering the body surface such as the face or body, but also the scalp.
  • Promoted skin regeneration herein may mean promoting the formation of new skin cells and promoting exfoliation of aged skin and includes regeneration of both normal skin cells or wounded skin cells.
  • hair may be described as hair as a general term for body hair and hair.
  • the hair includes both human and animal hair.
  • promoting wool means not only promoting the production of new hair, but also allowing existing hair to grow thick and healthy.
  • the present invention relates to a skin regeneration accelerator comprising an extract of an enzyme-treated edelweiss as an active ingredient.
  • enzyme refers to a substance which is capable of obtaining a high content of an extract when the substance constituting the edelweiss is extracted by physically or chemically modifying the substance.
  • the enzyme is not limited so long as it is an enzyme capable of obtaining an active ingredient of a plant at a high content and high yield rate, and specifically, includes a cell wall degrading enzyme.
  • cell wall degradation enzyme may refer to an enzyme that is involved in degradation of the plant cell wall.
  • the cell wall is generally composed of cellulose, hemicellulose, pectin substance, lignin, protein, magnesium, calcium and the like.
  • Cellulolytic enzymes include exo- ⁇ , 4 glucanase (fibrinase C1), endo- ⁇ , 4 glucanase (fibrinase Cx);
  • Hemicellulose degrading enzymes include xylanase, 1,3-xylanase, ⁇ -L-arbinofuranosidase, and the like;
  • Pectinase is a group of enzymes that cleave ⁇ -1,4 bonds of the main chains of pectin and pectinic acid (endo-polymethylgalacturonase (endo-PMG), endo-polygalacturonase (endo-).
  • endo-pectintranslylimase endo-PTE
  • endo-polygalacturonic acid trans-iriminase endo-PATE
  • exo-polymethylgalacturonase exo-PMG
  • exo- Pectin liberating the methyl group of polygalacturonase exo-PG
  • exo-Pectintranslylimase exo-PTE
  • exo-polygalacturonic acid trans-Iliaminase exo-PATE
  • pectin Methyl ester hydrolase pectin Methyl ester hydrolase
  • Plant cells unlike animal cells, are wrapped in a rigid cell wall.
  • the cell wall is composed of pectin and cellulose at the beginning, but is then cottoned to contain many lignin and hemicellulose in addition to cellulose.
  • Cellulase is an enzyme that breaks down cellulose, and processing it increases the efficiency of extracting active ingredients from plants as the hard cell wall is partially broken down. Therefore, when the cellulase is reacted with the cell wall degrading enzyme before extraction of edelweiss, the efficiency of extracting the active ingredient in the plant cell may be increased as compared with the case where the enzyme is not treated, thereby increasing the efficacy of the raw material.
  • edelweiss may be included in the form of an extract, or may be included as a ground powder of the herbal medicine, or as a dry ground powder of the herbal medicine, but is not limited thereto.
  • the edelweiss used in the present specification is not limited to the method of acquiring, can also be grown and used or purchased commercially available, can use some or all of the above-ground parts of the herb, preferably all of the above-ground parts can be used have.
  • enzyme-treated edelweiss extract may be obtained by treating cell edase on edelweis and extracting it.
  • the solvent includes at least one selected from the group consisting of water, an organic solvent, and a mixture of water and an organic solvent.
  • water includes distilled water or purified water
  • the organic solvent is selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform, for example, a lower alcohol having 1 to 5 carbon atoms. Including but not limited to one or more.
  • the enzyme may be selected from the group consisting of cellulase, xylanase, and arabinofuranosidase.
  • the extract may be obtained by adding 0.01 to 1% by weight of the cell wall degrading enzyme relative to the total weight of the edelweiss.
  • the cell wall degrading enzyme may be contained in 0.001 to 10% by weight relative to the total weight of the edelweiss. If the cell wall degrading enzyme is contained in less than 0.001% by weight, the increase in the content of chlorogenic acid, an active ingredient included in the edelweiss extract is insignificant, and if it contains more than 10% by weight, the content of other components is limited by the content of the cell wall degrading enzyme Done.
  • the edelweiss extract is 0.0011 to 9% by weight, 0.0012 to 8% by weight, 0.0013 to 7% by weight, 0.0014 to 6% by weight, 0.0015 to 5% by weight, 0.0016 to 4% by weight based on the total weight of the composition %, 0.0017 to 3% by weight, 0.0018 to 2% by weight or 0.0019 to 1% by weight.
  • the enzyme-treated edelweiss extract may contain 6 ppm or more of chlorogenic acid. In the case of containing such a range of chlorogen, it can have a better skin regeneration, hair growth promoting effect than the edelweiss extract without enzyme treatment.
  • the extract obtained from the edelweiss treated with the cell wall degrading enzyme of the present specification is at least 6.5ppm, at least 7ppm, at least 7.5ppm, at least 8ppm, at least 8.5ppm, at least 9ppm, based on the total extract weight of chlorogenic acid as an active ingredient. It may include more than 9.5ppm, more than 10ppm, more than 10.5ppm, more than 11ppm or more than 11.5ppm, may contain less than 100,000ppm or less than 10,000ppm.
  • Accelerators according to one aspect of the invention may comprise from 0.01% to 10% by weight, specifically from 0.1% to 5% by weight, more specifically from 0.5% to 3% by weight, based on the total weight of the accelerator. have.
  • the above range is not only suitable for showing the intended effect of the present invention, it can satisfy both the stability and safety of the composition, it may be appropriate to include in the above range in terms of cost-effectiveness. Specifically, when the edelweiss extract is less than 0.01% by weight, sufficient skin regeneration and hair growth promoting effect may not be obtained, and when it exceeds 10% by weight, safety and formulation stability may be lowered.
  • the present invention relates to a cosmetic composition
  • a cosmetic composition comprising the edelweiss extract.
  • the cosmetic composition has a skin regeneration effect, specifically it can heal wounds and reduce scars.
  • the cosmetic composition may promote hair growth, further prevent hair loss and promote wool.
  • Cosmetic compositions according to the invention may be provided in all formulations suitable for topical application.
  • it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a microneedle, a foam, or an aerosol composition.
  • Compositions of such formulations may be prepared according to conventional methods in the art.
  • the cosmetic composition according to the present invention may include other ingredients in addition to the above-mentioned substances within the range not impairing the main effect, preferably giving a synergistic effect to the main effect.
  • the cosmetic composition according to the present invention may further include a moisturizer, an emulsifier, a surfactant, a ultraviolet absorber, a preservative, a bactericide, an antioxidant, a pH adjuster, an organic and an inorganic pigment, a perfume, a cooling agent, or a restricting agent.
  • the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition have.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the edelweiss extract.
  • the pharmaceutical composition has a skin regenerating effect, and may specifically heal wounds and reduce scars.
  • the pharmaceutical composition may promote hair growth, further prevent hair loss and promote wool.
  • composition according to one aspect of the present invention may be administered orally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously, and the like.
  • Formulations for oral administration may be, but are not limited to, tablets, pills, soft and hard capsules, granules, powders, granules, solutions, emulsions or pellets. These formulations may contain, in addition to the active ingredient, diluents (e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine), glidants (e.g. silica, talc, stearic acid or polyethylene glycol), or binders (e.g. magnesium aluminum Silicates, starch pastes, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpyrrolidine). It may optionally contain pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, or sweeteners.
  • the tablets can be prepared by conventional mixing, granulating or coating methods.
  • Formulations for parenteral administration may be, but are not limited to, injections, drops, lotions, ointments, gels, creams, suspensions, emulsions, suppositories, patches or sprays.
  • the active ingredient of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Dosage determination based on these factors is within the level of one skilled in the art and its daily dosage may be, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / kg. May be, but is not limited to.
  • the present invention relates to a health food composition
  • a health food composition comprising an edelweiss extract.
  • the food composition has a skin regenerating effect, and may specifically heal wounds and reduce scars.
  • the food composition may promote hair growth, further prevent hair loss and promote wool.
  • the formulation of the food composition is not particularly limited, but may be, for example, formulated into a liquid such as tablets, granules, powders, drinks, caramels, gels, bars, and the like.
  • the food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials.
  • the daily dosage of the active ingredient is within the level of those skilled in the art, the daily dosage of which is for example from 0.1 mg / kg / day to 5000 mg / kg / day, more specifically from 50 mg / kg / day to 500 mg / kg / day, but is not limited thereto, and may vary depending on various factors such as age, health condition, and complications of the subject to be administered.
  • Edelweiss Leontopoium alpinum
  • 20 L of distilled water is added to 1 kg of dry edelweiss and extracted for 48 hours under a temperature condition of 4 ° C.
  • the precipitate is filtered through a 250 mesh filter, and then again filtered through a 0.5 ⁇ m filter.
  • the edelweiss extract is obtained by filtration through a 0.5 ⁇ m filter.
  • Edelweiss Leontopoium alpinum
  • 2 L of distilled water is added and 100 g of cellulase is added to adjust the pH to 4.8.
  • the reaction is carried out at 40 ° C. for 72 hours.
  • 18 L of distilled water is added and extracted for 48 hours under the temperature condition of 4 °C. After that, it is filtered through a 250 mesh filter and once again filtered through a 3 ⁇ m filter. After decolorization and deodorization with activated carbon, the edelweiss extract is obtained by filtration through a 0.5 ⁇ m filter.
  • GSK3, APC and Axin protein complexes that inhibit intracellular beta-catenin are inhibited and beta-catenin moves into the cell nucleus and is involved in development and hair growth.
  • Various genes are expressed.
  • Beta-catenin is a transcriptional regulator attached to a specific nucleotide sequence of the chromosome, and a plasmid vector obtained by artificially combining the beta-catenin attachment nucleotide sequence followed by a Gaussian luciferase gene sequence is prepared for HEK293 (human embryos). Renal cell line).
  • the transformed cell line thus prepared is resistant to G418 antibiotics, and when cultured in a medium containing G418, only the transformed cell line can be selectively cultured.
  • the transformed HEK293 cell line having the Wint / Beta catenin signal transduction system thus obtained was treated with the Edelweiss extract of Example, and then Gaussian luciferase assay kit (BioLabs) increased the expression of Gaussian luciferase. Confirmed.
  • the transgenic HEK293 cells 10% bovine serum serum (Fetal bovine serum) (FBS) and G418 500 ⁇ g / Dulbecco's modified Eagle's medium with ml containing; a (DMEM Gibco BRL, Gaithersburg, MD , USA) 5% CO 2 Incubated for 24 hours in an incubator at 37 °C.
  • Cells cultured in 96-well plates for 24 hours were treated with 2 ppm and 5 ppm of edelweiss extract of Example 1 and 2ppm and 5ppm of enzyme-treated edelweiss extract of Example 2, respectively, and then cultured in an incubator for 48 hours. .
  • VPA sodium valproic acid
  • GSK-3 ⁇ glycogen synthase kinase 3-beta
  • the edelweiss extract promotes the wint / beta catenin signal transduction of stem cells. It can be seen that the edelweiss extract has the effect of promoting skin regeneration and hair growth.
  • Human immortalized dermal papilla is an immortalized dermal papilla cell prepared by transducing human dermal papilla cells with a vector containing Simian virus 40 large T (SV40T) and c-myc. cell) was used. The cell lines were incubated for 24 hours in an incubator at 5% CO 2 , 37 ° C. in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) containing 10% bovine serum serum (FBS), respectively. 10 ppm and 20 ppm edelweiss extracts of 1 were treated.
  • DMEM Dulbecco's modified Eagle's medium
  • FBS bovine serum serum
  • DMSO methyl methoxysulfoxide
  • VPA sodium valproic acid
  • GSK-3 ⁇ glycogen synthase kinase 3 beta
  • 166 ppm was used.
  • the cells were washed twice with PBS Phosphate buffered saline on ice, and then 300 ⁇ l ALP assay buffer (ALP assay kit, BioVision, Catalog # K412-500) was placed on the cells and scraped. The scrapes were collected in eppendorf tubes.
  • the collected cells were awakened on a probe sonicator on ice, centrifuged at 4 ° C., 12,000 rpm for 5 minutes, and the supernatant was taken.
  • Bio-rad DC protein kit Biorad, cat.no. 500-0111
  • the concentration of cellular protein was measured.
  • the alkaline phosphatase activity of the test substance was evaluated in terms of the measured concentration values.
  • nitrophenyl phosphate which is a substrate of alkaline phosphatase enzyme
  • pNPP tab ALP assay kit, BioVision, Catalog # K412-500 assay buffer, prepared at a concentration of 5 mM, and reacted with cellular proteins. Put it.
  • the pNPP dissolved in 1mM concentration was added to 4 ⁇ 20 ⁇ by concentration, and the standard solution was prepared by adding an ALP enzyme to cause the enzymatic degradation reaction of pNPP.
  • a 96-well plate containing test material and standard solution was placed in a 25 ° C. incubator for 1 hour, and then, a stop solution was added, and the absorbance was measured at 405 nm.
  • the activity value of the enzyme was determined by the amount of pNP produced by degradation. The results are shown in FIG.
  • the edelweiss extract increased the alkaline phosphatase activity in the dermal papilla cells.
  • the edelweiss extract can promote hair production by maintaining and activating the stem cell nature of the dermal papilla cell line.
  • the keratin proteins that make up hair are produced in hair root keratinocytes, which are differentiated from dermal papilla cells. Therefore, if the edelweiss extract promotes the activity of the dermal papilla cells, it may promote the activity of keratinocytes differentiated therefrom and further promote hair production.
  • iDPc Human immortalized dermal papilla cell
  • the cell line is an immortalized papillary cell prepared by transducing human dermal papilla cells with a vector containing Simian virus 40 large T (SV40T) and c-myc.
  • SV40T Simian virus 40 large T
  • the cell lines were incubated for 24 hours in an incubator maintained at 5% CO 2 , 37 ° C. in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) containing 10% bovine serum serum (FBS).
  • DMEM Dulbecco's modified Eagle's medium
  • FBS bovine serum serum
  • the edelweiss extract significantly increased the proliferation of dermal papilla cells. It can be seen that the edelweiss extract may promote the growth of dermal papilla cells, and further promote the activity and hair production of keratinocytes.
  • the enzyme treated edelweiss extract increased the growth of dermal papilla cells compared to before the enzyme treatment. It can be seen that the enzyme-treated edelweiss extract can promote the growth of dermal papilla cells and further promote the activity and hair production of keratinocytes.
  • Hair follicles were isolated from the scalp and scalp tissue of a 55 year old male with William's E medium (L-glutamine (2 mM), insulin (10 ⁇ g / ml), hydrocortisone (40 ng / ml), antibiotics (1%), fungizon (1%). )). After 3 days of culture, the hair follicles were grown, cut to 3 mm, and the selected hair follicle tissues were treated with no drug in the control group, and the experimental group was treated with minoxidil 10 ⁇ M and the Edelweiss extract of Example 1 50 ppm and 100 ppm. After 3 days, 7 days, 11 days, and 14 days after drug treatment, length measurement and photographing were performed, respectively. The results are shown in FIG.
  • the length of the growth occurs when the hair is in the anagen phase of the hair cycle, and the hair begins to fall out when it is transferred to the catagen.
  • the ratio of hair follicles in the growing stage was higher than that of minoxidil at both concentrations, indicating an effect of reducing hair follicles that metastasize to hair growth.
  • Chlorogenic acids, luteolin, apigenin, leontopodic acid and the like are known as compounds present in the edelweiss extract.
  • the indicators can be qualitatively and quantitatively analyzed by high performance liquid chromatography (HPLC) analysis.
  • Chlorogenic acid is a kind of polyphenolic compound contained in coffee in large quantities and is known to have an antioxidant effect. Since the content of the chlorogenic acid was the highest when the content of the indicator substance in the edelweiss extract was analyzed, the content of chlorogenic acid was used in the present invention to analyze the extraction efficiency of the enzyme treatment extraction method.
  • the edelweiss extract of Example 1 and the enzyme treatment of the edelweiss extract of Example 2 were analyzed the stock solution, and chlorogenic acid used as a standard was dissolved in 50% methanol at a concentration of 5 g / ml.
  • the HPLC instrument used in the analysis was a Water Alliance 2695E model HPLC, the detector was a PDA detector 2998 model from Water, and the column was Mightysil-RP18 (4.6 x 250, 5 um). Standard was prepared at 2,5,10 ⁇ g / mL to draw a 3-point calibration curve to quantify the chlorogenic acid in the edelweiss extract.
  • the retention time of chlorogenic acid is 17 minutes and the detection wavelength is 326 nm.
  • the DPPH antioxidant assay was used to evaluate the antioxidant effect of chlorogenic acid, an edelweiss index component. Oxidation reactions occurring in the body are mainly caused by free radicals, and this action is known to lead to the aging of cells and the development of cancer. Therefore, inhibition of free radical production in the body may eventually be associated with antioxidant and anti-aging in the body, and since this antioxidant effect is difficult to experiment with free radicals in the body, DPPH (2,2-diphenyl-1-picrylhydrazyl) radicals may be It is used universally. DPPH radicals have a deep purple color. When they react with antioxidant compounds, they turn to pale yellow color and measure their absorbance at 517 nm. Higher antioxidants have a lighter yellow color and lower absorbance.
  • Ointments are prepared according to conventional methods with the compositions described in the table below.
  • a hair lotion is prepared according to a conventional method with the composition described in the table below.
  • a cream is prepared according to a conventional method with the composition described in the table below.
  • Table 4 ingredient Content (% by weight) Purified water Remaining amount glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 45.0 Beta Glucan 7.0 Carbomer 0.1 Edelweiss extract 1.5 Caprylic Capric Triglycerides 3.0 beeswax 4.0 Cetearyl Glucoside 1.5 Sesqui oleic acid sorbitan 0.9 Vaseline 3.0 antiseptic Quantity incense Quantity Pigment Quantity Triethanol amine 0.1
  • the above ingredients are mixed according to a conventional method for preparing a health beverage, then stirred and heated at 85 ° C. for about 1 hour, and then the resulting solution is filtered and sterilized.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

Disclosed is a skin regeneration and hair growth promoter containing an edelweiss extract as an active ingredient. In addition, the present invention relates to a promoter containing an enzyme-treated edelweiss extract, and more specifically, to a promoter containing a cell wall-degrading enzyme-treated edelweiss extract.

Description

에델바이스 추출물을 포함하는 피부 재생 및 모발 성장 촉진제Skin regeneration and hair growth promoter including edelweiss extract
본 발명은 에델바이스 추출물을 포함하는 피부 재생 및 모발 성장 촉진제에 관한 것이다.The present invention relates to a skin regeneration and hair growth promoter comprising an edelweiss extract.
탈모는 성장 주기에 따라 휴지기성 탈모와 성장기성 탈모로 구분할 수 있으며, 휴지기성 탈모로는 안드로겐에 의한 남성형 탈모, 여성의 산후 탈모 또는 내분비 질환에 의한 탈모를 들 수 있고, 성장기성 탈모로는 원형 탈모, 반흔성 탈모 또는 두부 백선에 의한 탈모 등을 들 수 있다. 또한 국소 감염, 내분비 장애, 유전 인자 및 자가 면역 등에 의해서도 탈모가 발생하는 것으로 알려져 있다.Hair loss can be classified into resting hair loss and growing hair loss according to the growth cycle, and the resting hair loss includes androgenetic alopecia caused by androgen, postpartum hair loss of women or endocrine disease, and rounded hair growth by circular growth. Hair loss, scar hair loss, or hair loss due to ringworm. In addition, hair loss is also known to occur due to local infection, endocrine disorders, genetic factors and autoimmunity.
현재 대표적인 탈모 방지제로는 미국 FDA에서 승인한 프로페시아와 미녹시딜이 있다. 이러한 약물은 임상적으로 분명한 효과를 보이나 성기능 장애 및 피부 자극 등 부작용 또한 나타낼 뿐만 아니라 여성은 사용이 불가능하거나 극히 제한적인 함량으로만 사용이 가능하다. 따라서 상기와 같은 단점을 가지지 않도록 새로운 기전을 통하면서도 성별 제한 없이 안전하게 사용할 수 있는 천연물 제제에 대한 관심이 높아지고 있다.Representative anti-hair loss agents currently include Propecia and Minoxidil, which are approved by the US FDA. These drugs have clinically definite effects, but also have side effects such as sexual dysfunction and skin irritation, and women can not use or use only in extremely limited amounts. Therefore, there is a growing interest in natural products formulations that can be safely used without any gender restrictions, but through a new mechanism so as not to have the above disadvantages.
본 발명은 우수한 피부 재생 촉진 효과를 가지는 피부 재생 촉진제 및 뛰어난 모발 성장 촉진 효과를 가지는 모발 성장 촉진제를 제공하고자 한다.The present invention seeks to provide a skin regeneration accelerator having an excellent skin regeneration promoting effect and a hair growth promoter having an excellent hair growth promoting effect.
또한 본 발명의 목적은 에델바이스 추출물에 포함되어 있는 유효물질의 함량을 증가시켜, 더욱 개선된 피부 재생 및 모발 성장 효과를 가지는 촉진제를 제공하는 데 있다. It is also an object of the present invention to increase the content of the active substance contained in the edelweiss extract, to provide an accelerator having a further improved skin regeneration and hair growth effect.
본 발명의 일측면은 에델바이스 추출물을 유효 성분으로 포함하는 피부 재생 촉진제 및 모발 성장 촉진제를 제공한다.One aspect of the present invention provides a skin regeneration accelerator and a hair growth promoter comprising an edelweiss extract as an active ingredient.
본 발명의 다른 일측면은 상기 촉진제를 포함하는 화장료 조성물 및 약학 조성물을 제공한다.Another aspect of the present invention provides a cosmetic composition and a pharmaceutical composition comprising the accelerator.
또한 본 발명은 세포벽 분해효소로 처리한 에델바이스의 추출물을 유효성분으로 포함하는 피부 재생 촉진제를 제공한다.The present invention also provides a skin regeneration accelerator comprising an extract of Edelweiss treated with cell wall degrading enzyme as an active ingredient.
본 발명에 따른 제제는 에델바이스 추출물을 유효 성분으로 포함함으로써, 윈트/베타-카테닌(Wnt/beta-catenin) 신호 전달을 촉진하여 우수한 피부 재생 효과, 구체적으로 뛰어난 피부 상처 치유 및 흉터 감소 효과를 나타낼 수 있다. 또한 상기 제제는 윈트/베타-카테닌 신호 전달을 촉진할 뿐만 아니라, 모유두 세포의 줄기세포를 활성화하고 모낭의 모유두 세포의 증식을 촉진하므로 우수한 모발 성장 촉진 효과, 나아가 탈모 방지 및 양모 촉진 효과를 나타낼 수 있다.The formulation according to the present invention may include an edelweiss extract as an active ingredient, thereby promoting Wnt / beta-catenin signal transduction, thereby exhibiting excellent skin regeneration effect, specifically excellent skin wound healing and scar reduction effect. have. In addition, the preparation not only promotes wint / beta-catenin signal transduction, but also activates stem cells of the dermal papilla cells and promotes the proliferation of dermal papilla cells of the hair follicles, thereby exhibiting an excellent hair growth promoting effect, further preventing hair loss and promoting wool. have.
또한 본 발명에 따른 효소 처리 에델바이스의 추출물을 포함하는 촉진제는 식물 세포 내 유효 성분의 추출 효율을 증가시킬 수 있어서, 클로로겐산의 함량이 급격히 증가하였고, 고함량의 클로로겐산을 가짐에 따라 항산화능이 증가하였으며, 윈트/베타-카테닌(Wnt/beta-catenin) 신호 전달을 더욱 촉진하여 개선된 피부 재생 효과, 구체적으로 뛰어난 피부 상처 치유 및 흉터 감소 효과, 모발 성장 촉진 효과를 나타낼 수 있다.In addition, the accelerator including the extract of the enzyme-treated edelweiss according to the present invention can increase the extraction efficiency of the active ingredient in the plant cell, the content of chlorogenic acid is rapidly increased, and the antioxidant activity is increased with a high content of chlorogenic acid, By further promoting the transmission of Wnt / beta-catenin (Wnt / beta-catenin) signal can exhibit an improved skin regeneration effect, specifically excellent skin wound healing and scar reduction effect, hair growth promoting effect.
도 1은 에델바이스 추출물이 줄기세포의 윈트/베타-카테닌(Wnt/beta-catenin) 신호 전달을 촉진함을 보여주는 그래프이다.1 is a graph showing that Edelweiss extract promotes Wnt / beta-catenin signal transduction of stem cells.
도 2는 에델바이스 추출물이 모유두 세포주의 줄기세포성을 유지 및 활성화시킴을 보여주는 그래프이다.2 is a graph showing that the edelweiss extract maintains and activates the stem cell nature of the dermal papilla cell line.
도 3은 에델바이스 추출물의 모낭 모유두 세포 증식 촉진 효과를 보여주는 그래프이다.Figure 3 is a graph showing the hair follicle dermal papilla cell growth promoting effect of the edelweiss extract.
도 4는 에델바이스 추출물의 모낭에서 모발 성장 촉진 효과 및 성장기 모낭을 유지하는 효과를 보여주는 그래프이다.Figure 4 is a graph showing the hair growth promoting effect and the effect of maintaining the hair follicle growth period in the hair follicle of Edelweiss extract.
도 5은 효소처리 에델바이스 추출물이 줄기세포의 윈트/베타-카테닌(Wnt/beta-catenin) 신호 전달을 촉진함을 보여주는 그래프이다.5 is a graph showing that the enzyme-treated Edelweiss extract promotes Wnt / beta-catenin signal transduction of stem cells.
도 6는 효소처리 에델바이스 추출물의 모낭 모유두 세포 증식 촉진 효과를 보여주는 그래프이다.Figure 6 is a graph showing the hair follicle dermal papilla cell growth promoting effect of the enzyme treatment Edelweiss extract.
도 7은 에델바이스 추출물과 효소처리 에델바이스 추출물에 포함된 지표 성분인 클로로겐산(chlorogenic acid)의 함량을 비교한 그래프이다.Figure 7 is a graph comparing the content of chlorogenic acid as an indicator component contained in the edelweiss extract and the enzyme treatment edelweiss extract.
도 8는 에델바이스 지표 성분인 클로로겐산의 항산화 효능을 나타낸 그래프이다.8 is a graph showing the antioxidant efficacy of chlorogenic acid as an edelweiss index component.
인체의 각 조직에는 그 조직을 구성하는 세포들을 생산하는 성체 줄기세포가 존재한다. 피부 또는 모발을 만들어내는 세포 또한 피부 또는 모낭에 존재하는 줄기세포에서 유래한다.Each tissue in the human body contains adult stem cells that produce the cells that make up that tissue. The cells that make up skin or hair are also derived from stem cells present in the skin or hair follicles.
줄기세포는 일반적으로, 어떤 조직으로든 발달할 수 있는 전능세포(pluripotent cell)를 지칭한다. 이는 반복 분열하여 자신을 만들어 내는 자기 재생산(self-renewal) 능력 및 환경에 따라 특정한 기능을 지닌 세포로 분화할 수 있는 다분화 능력을 가진다. 이러한 줄기세포는 크게 배아 줄기세포(embryonic stem cells)와 성체 줄기세포(adult stem cells)로 나눌 수 있다.Stem cells generally refer to pluripotent cells that can develop into any tissue. It has the ability to self-renewal to regenerate itself and to differentiate into cells with specific functions depending on the environment. These stem cells can be roughly divided into embryonic stem cells (adryonic stem cells) and adult stem cells (adult stem cells).
배아 줄기세포는 남성의 생식세포인 정자와 여성의 생식세포인 난자의 수정으로 생성된 수정란에서 유래한다. 이는 다양한 종류의 세포로 분화할 수 있는 능력을 가져 전분화능 줄기세포라고도 한다. 배아 줄기세포는 대량 증식 및 거의 모든 신체 세포로의 분화가 가능하며, 면역 거부 반응이 없어 타인뿐만 아니라 타종에게도 이식이 가능하다는 장점을 가진다. 그러나 분화 조절이 어려워 암세포로 될 가능성이 있으므로 기술의 정밀함을 요하며, 수정란의 파괴가 수반되므로 윤리적으로 문제가 될 수도 있다.Embryonic stem cells are derived from fertilized eggs produced by fertilization of sperm, a male germ cell and an egg, a female germ cell. It is also called pluripotent stem cell because it has the ability to differentiate into various cell types. Embryonic stem cells are capable of mass proliferation and differentiation into almost all body cells, and have no immune rejection reaction, so that they can be transplanted to other species as well as others. However, it is difficult to control differentiation, which may lead to cancer cells, requiring technical precision, and accompanied by destruction of the fertilized egg, which may be an ethical problem.
성체 줄기세포는 일반적으로, 필요한 때에 특정한 조직의 세포로 분화하는 세포를 의미하며, 신체 각 조직에 대개 극히 소량만이 존재한다. 즉, 골수세포의 성체 줄기세포는 혈구세포로, 피부 성체 줄기세포는 피부로, 후각신경세포의 성체 줄기세포는 후각신경세포로만 분화되도록 정해져 있다. 이러한 성체 줄기세포는 분화가 안정적이어서 암세포로 될 가능성이 거의 없으며, 배아 줄기세포와는 달리 수정란을 파괴시키지 않으므로 윤리적으로도 문제되지 않는다.Adult stem cells generally refer to cells that differentiate into cells of specific tissues when needed, and usually only a small amount is present in each tissue of the body. That is, adult stem cells of bone marrow cells are differentiated into hematopoietic cells, skin adult stem cells into skin, and adult stem cells of olfactory neurons into olfactory neurons. These adult stem cells are stable and are unlikely to become cancer cells, and unlike embryonic stem cells, they do not destroy fertilized eggs, so it is not ethically problematic.
모낭 줄기세포는 모낭에 존재하면서 피부 및 모발을 구성하는 세포를 만들어내는 성체 줄기세포이며, 이는 벌지 줄기세포(Bulge stem cell)라고도 불리는 상피 세포의 유래가 될 수 있는 모낭 줄기세포, 간엽 줄기세포 유래의 모낭 모유두 세포 및 신경 줄기세포 유래의 멜라닌 형성 줄기세포라는 크게 세 가지 종류로 나눌 수 있다.Hair follicle stem cells are adult stem cells that exist in the hair follicles and produce the cells that make up the skin and hair, which are derived from hair follicle stem cells and mesenchymal stem cells, which may be derived from epithelial cells, also called bulge stem cells. The hair follicle dermal papilla cells and neural stem cells derived from melanin-forming stem cells can be largely divided into three types.
이하, 본 발명을 상세하게 설명한다.EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.
본 발명의 일측면은 에델바이스 추출물을 유효 성분으로 포함하는 피부 재생 촉진제를 제공한다.One aspect of the present invention provides a skin regeneration accelerator comprising an edelweiss extract as an active ingredient.
본 발명의 다른 일측면은 에델바이스 추출물을 유효 성분으로 포함하는 모발 성장 촉진제를 제공한다.Another aspect of the present invention provides a hair growth promoter comprising an edelweiss extract as an active ingredient.
본 발명의 일측면에 있어서, 에델바이스 추출물은 효소처리 에델바이스 추출물일 수 있다.In one aspect of the invention, the edelweiss extract may be an enzyme-treated edelweiss extract.
본 발명의 일 관점인 피부 재생 촉진제에 있어서, 상기 촉진제는 피부 상처를 치유할 수 있다. In the skin regeneration accelerator which is an aspect of the present invention, the promoter may heal a skin wound.
본 발명의 일 관점인 피부 재생 촉진제에 있어서, 상기 촉진제는 탈모를 방지하거나 또는 양모를 촉진할 수 있다. In the skin regeneration accelerator which is an aspect of the present invention, the accelerator may prevent hair loss or promote wool.
본 발명의 일 관점인 피부 재생 촉진제에 있어서, 상기 촉진제는 윈트 신호 (Wnt signal)를 활성화할 수 있다. In the skin regeneration accelerator, which is an aspect of the present invention, the promoter may activate a Wnt signal.
윈트/베타-카테닌(Wnt/beta-catenin) 신호 전달은 생명체의 발생과 관련 있는 신호 전달 체계이며, 피부 생성 및 모낭의 발생에 작용하는 것으로 알려져 있다. 나아가 피부에 상처가 생기면 피부 조직 회복 과정에서 윈트 신호 전달이 필수적으로 발현되어 상피 세포의 분화를 촉진하는 것으로 알려져 있다. 따라서 윈트 신호 전달이 촉진되면 상피 세포의 분화가 촉진되어 피부 재생이 촉진될 수 있고, 나아가 피부 상처의 치유가 촉진될 수 있다. 본 명세서의 효소 처리 에델바이스 추출물은 줄기세포의 윈트/베타-카테닌(Wnt/beta-catenin) 신호 전달을 촉진한다. 따라서 이를 포함하는 제제는 피부 재생을 촉진할 수 있으며, 구체적으로 피부 상처의 치유를 촉진할 수 있다.Wnt / beta-catenin signaling is a signaling system involved in the development of living organisms and is known to act on skin formation and hair follicle development. Furthermore, when a wound occurs on the skin, it is known that wint signal transduction is essential during skin tissue recovery to promote differentiation of epithelial cells. Therefore, if the wint signal is promoted, the differentiation of epithelial cells may be promoted to promote skin regeneration, and further, the healing of skin wounds may be promoted. The enzyme-treated edelweiss extract of the present disclosure promotes the transmission of Wnt / beta-catenin in stem cells. Therefore, the formulation containing the same may promote skin regeneration, and in particular, may promote healing of skin wounds.
모발은 성장기-퇴행기-휴지기의 주기를 거치면서 성장과 탈락을 반복한다. 그 중 성장기에 모낭 줄기세포들이 분화하면서 새로운 모발이 형성된다. 한편, 윈트 단백질을 마우스에 처리하면 모발 성장이 촉진되고, 윈트 유전자를 녹-다운(Knock-down) 시킨 마우스에서는 모발 성장이 저해된다고 알려진 바 있다. 이는 모낭 줄기세포에 존재하는 윈트/베타-카테닌 신호 전달을 촉진하는 물질이 모발 성장을 촉진할 수 있음을 의미한다. 이러한 메커니즘을 통해 모발 성장을 촉진하는 물질은 남성 호르몬 및/또는 혈액 순환 조절을 통해 모발 성장 촉진에 관여하는 것이 아니므로, 남성 호르몬을 억제하거나 혈액 순환을 촉진하는 방법으로는 해결되지 않았던 심한 탈모 및 여성형 탈모를 개선할 수 있을 것이다. 또한 모유두 세포의 줄기 세포가 활성화되면 모유두 세포의 활성이 촉진되어 모발 성장이 촉진될 수 있다. 에델바이스 추출물은 줄기세포의 윈트/베타-카테닌(Wnt/beta-catenin) 신호 전달을 촉진하며, 모유두 세포의 줄기 세포를 활성화시킨다. 또한 에델바이스 추출물은 모낭 모유두 세포의 증식을 촉진한다. 따라서 에델바이스 추출물을 포함하는 제제는 모발 성장을 촉진하며, 나아가 탈모를 방지하고 양모를 촉진할 수 있다. 또한 에델바이스 추출물을 포함하는 모발 성장 촉진제는 기존의 모발 성장 촉진제로 알려진 미녹시딜보다 우수한 모발 성장 촉진, 탈모 방지 및 양모 촉진 효과를 가질 수 있으며, 성기능 장애 또는 피부 자극과 같은 부작용을 거의 나타내지 않으며, 성별을 불문하고 사용될 수 있다.Hair repeats growth and fall through the growth-degeneration-rest phase. Among them, hair follicle stem cells differentiate during growth, forming new hair. On the other hand, the treatment of the winte protein in the mouse promotes hair growth, it has been known that hair growth is inhibited in mice knocked down the wint gene. This means that substances that promote wint / beta-catenin signal transduction present in hair follicle stem cells can promote hair growth. Since substances that promote hair growth through this mechanism are not involved in promoting hair growth through the regulation of testosterone and / or blood circulation, severe hair loss and which have not been addressed by methods of inhibiting testosterone or promoting blood circulation and Female hair loss can be improved. In addition, when the stem cells of the dermal papilla cells are activated, the activity of the dermal papilla cells may be promoted to promote hair growth. Edelweiss extract promotes Wnt / beta-catenin signaling in stem cells and activates stem cells in dermal papilla cells. Edelweiss extract also promotes the growth of hair follicle dermal papilla cells. Therefore, the formulation containing the edelweiss extract can promote hair growth, further prevent hair loss and promote wool. In addition, the hair growth accelerator including the edelweiss extract may have a superior hair growth promoting, hair loss prevention and wool promoting effect than minoxidil, which is known as a conventional hair growth promoter, has little side effects such as sexual dysfunction or skin irritation, and has no gender. Can be used regardless.
본 발명의 일 관점인 촉진제에 있어서, 상기 에델바이스는 레온토포이움 속 (Leontopoium sp.) 식물을 포함한다. 본 발명의 일 관점인 촉진제에 있어서, 상기 에델바이스는 레온토포이움 알피늄(Leontopoium alpinum)일 수 있다. In one embodiment of the present invention, the edelweiss includes a plant of the genus Leontopoium sp. In one embodiment of the present invention, the edelweiss may be Leontopoium alpinum .
본 명세서에서, 상기 "에델바이스"는 레온토포이움 속 (Leontopoium sp.) 식물일 수 있다. 상기 레온토포이움 속 (Leontopoium sp.) 식물은 레온토포이움 알피늄(Leontopoium alpinum), 레온토포이움 안데르소니 (Leontopodium andersonii), 레온토포이움 아르테미시포리움 (Leontopodium artemisiifolium), 레온토포이움 아우란티아쿰 (Leontopodium aurantiacum), 레온토포이움 브라키아크티스 (Leontopodium brachyactis), 레온토포이움 카로세파룸 (Leontopodium calocephalum), 레온토포이움 캄페스테 (Leontopodium campestre), 레온토포이움 추이 (Leontopodium chuii), 레온토포이움 콩로바튬 (Leontopodium conglobatum), 레온토포이움 코레아눔 (Leontopodium coreanum), 레온토포이움 데데켄시 (Leontopodium dedekensii), 레온토포이움 데라바야눔 (Leontopodium delavayanum), 레온토포이움 디스코로 (Leontopodium discolor), 레온토포이움 파긴겐스 (Leontopodium fangingense), 레온토포이움 파우리에이 (Leontopodium fauriei), 레온토포이움 포레스티아눔 (Leontopodium forrestianum), 레온토포이움 프란체티 (Leontopodium franchetii), 레온토포이움 지랄디 (Leontopodium giraldii), 레온토포이움 하스셔이데스 (Leontopodium haastioides), 레온토포이움 하라이사넨스 (Leontopodium hallaisanense), 레온토포이움 하프로필로이데스 (Leontopodium haplophylloides), 레온토포이움 하라키넨스 (Leontopodium hayachinense), 레온토포이움 히마라야눔 (Leontopodium himalayanum), 레온토포이움 자코티아눔 (Leontopodium jacotianum) 및 레온토포이움 자포니쿰 (Leontopodium japonicum)으로 구성된 군에서 선택되는 하나 이상의 식물을 포함할 수 있다. In the present specification, the "Edelweiss" may be a plant of the genus Leontopoium sp. Leontopoium sp. Plants are Leontopoium alpinum , Leontopodium andersonii , Leontopodium artemisiifolium , Leontopoium auran Tiacum ( Leontopodium aurantiacum ), Leontopodium brachyactis , Leontopodium calocephalum , Leontopodium campestre , Leontopoium chuii , Leontopodium chuii , Umm beans Rover lithium (Leontopodium conglobatum), Leon topoyi help Correa num (Leontopodium coreanum), Leon topoyi help Dedeman Ken City (Leontopodium dedekensii), Leon topoyi help to Surabaya yanum (Leontopodium delavayanum), with Leon topoyi help disco (Leontopodium discolor) Leon topoyi help pagin Regensburg (Leontopodium fangingense), Leon topoyi help us this file (Leontopodium fauriei), On topoyi help Forres Tia num (Leontopodium forrestianum), Leon topoyi help program rancheti (Leontopodium franchetii), Leon topoyi help Fuck di (Leontopodium giraldii), Leon topoyi help Haas syeoyi Death (Leontopodium haastioides), Leon topoyi Be Umm Director nenseu (Leontopodium hallaisanense ), Leontopodium haplophylloides , Leontopodium hayachinense , Leontopodium himalayanum , Leontopodium jacotianum and Leontopodium jacotianum and Leontopodium haplophylloides It may include one or more plants selected from the group consisting of Leontopodium japonicum .
본 발명의 일 측면에서, 에델바이스(Leontopoium alpinum)는 쌍떡잎식물 초롱꽃목 국화과의 여러해살이풀로 주로 건조한 곳에서 서식하는 고산식물이다. 잎은 뿌리에서 비교적 많이 나오고 줄기에 약간 있으며 선형이다. 줄기 끝에 포가 모여 달려서 사방으로 퍼지고 중앙에 약간의 두상화가 달린다.In one aspect of the invention, Edelweiss ( Leontopoium alpinum ) is a perennial plant of the dicotyledon plant Campanula Asteraceae is an alpine plant that lives primarily in dry places. The leaves are relatively high in the roots, slightly on the stems, and linear. At the end of the stem, the squirrel gathers, spreads out all over it, with a slight heading in the middle.
본 명세서에서 사용되는 에델바이스는 추출물의 형태로 포함되거나, 생약 자체의 분쇄물, 또는 생약의 건조 분쇄물로서 포함될 수 있으나, 이에 제한되는 것은 아니다. 아울러 본 명세서에서 사용되는 에델바이스는 그 입수 방법에 제한이 없으며, 재배하여 사용하거나 시판되는 것을 구입하여 사용할 수도 있으며, 초본의 지상부의 일부 또는 전부를 사용할 수 있으며, 바람직하게는 지상부의 전부를 사용할 수 있다. As used herein, edelweiss may be included in the form of an extract, or may be included as a ground powder of the herbal medicine, or as a dry ground powder of the herbal medicine, but is not limited thereto. In addition, the edelweiss used in the present specification is not limited to the method of acquiring, can also be grown and used or purchased commercially available, can use some or all of the above-ground parts of the herb, preferably all of the above-ground parts can be used have.
본 명세서에서 "추출물"은 추출 방법, 추출 용매, 추출된 성분 또는 추출물의 형태를 불문하고, 천연물의 성분을 뽑아냄으로써 얻어진 물질을 모두 포함하는 것이며 또한 천연물의 성분을 뽑아내어 얻어진 물질을 추출 후 다른 방법으로 가공 또는 처리하여 얻어질 수 있는 물질을 모두 포함하는 광범위한 개념이다.As used herein, the term "extract" includes all materials obtained by extracting the components of natural products, regardless of the extraction method, extraction solvent, extracted components or the form of the extract, and extracts the substances obtained by extracting the components of natural products. It is a broad concept that includes all of the materials that can be obtained by processing or processing in a method.
본 명세서에서 "에델바이스 추출물"은 추출 방법, 추출 용매, 추출된 성분 또는 추출물의 형태를 불문하고, 에델바이스의 성분을 뽑아냄으로써 얻어진 물질을 모두 포함하는 것이며 그 성분을 뽑아내는 과정에서 열, 산(acid), 염기(base), 효소 등으로 처리하는 공정을 포함하는 추출 방법을 통해 얻어진 물질을 포함하며 또한 에델바이스의 성분을 뽑아내어 얻어진 물질을 추출 후 다른 방법으로 가공 또는 처리하여 얻어질 수 있는 물질을 모두 포함하는 광범위한 개념이다.In the present specification, "edelweiss extract" includes all materials obtained by extracting the components of edelweis, regardless of the extraction method, the extraction solvent, the extracted components or the form of the extract, and heat, acid (acid) in the process of extracting the components. Material obtained through the extraction method including the step of treating with a base, an enzyme, and the like, and a material obtained by extracting an edelweiss component and then processing or treating it by another method. All inclusive is a broad concept.
본 발명의 일측면에서, 에델바이스 추출물은 에델바이스를 세척하고 건조하는 단계; 건조한 에델바이스를 용매 추출하는 단계; 및 추출한 에델바이스를 여과하는 단계를 거쳐 수득할 수 있다. 상기에서 용매는 물, 유기 용매 및 물과 유기 용매의 혼합물로 이루어진 군에서 선택된 하나 이상을 포함한다. 상기에서 물은 증류수 또는 정제수를 포함하고, 유기 용매는 C1~C5의 저급 알코올을 예로 들 수 있는 알코올, 아세톤, 에테르, 에틸아세테이트, 디에틸에테르, 에틸메틸케톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상을 포함하나, 이에 제한되는 것은 아니다.In one aspect of the invention, the edelweiss extract is a step of washing and drying the edelweiss; Solvent extraction of the dry edelweiss; And it can be obtained through the step of filtering the extracted edelweiss. In the above, the solvent includes at least one selected from the group consisting of water, an organic solvent, and a mixture of water and an organic solvent. In the above, water includes distilled water or purified water, and the organic solvent is selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform, for example, a lower alcohol having 1 to 5 carbon atoms. Including but not limited to one or more.
상기 에델바이스 추출물은 에델바이스-C1~C6 알코올 추출물을 포함할 수 있고, 구체적으로 상기 알코올은 메탄올 또는 에탄올일 수 있다. The edelweiss extract may include an edelweiss-C 1 ~ C 6 alcohol extract, specifically, the alcohol may be methanol or ethanol.
본 명세서에서 상기 에델바이스 추출물은 물, C1-C6 알콜, 및 이들이 조합으로 구성된 그룹에서 선택된 용매의 조추출물일 수 있다. 상기 C1-C6 알콜은 구체적으로 메탄올일 수 있다. 에델바이스를 용매로 추출 시, 에델바이스의 약 5 내지 15배 정도에 해당하는 용매를 가하여 추출하는 것이 바람직하며, 구체적으로 약 10 배의 용매를 가하여 추출하는 것이 바람직하나, 이에 한정되는 것은 아니다. 상기 추출은 가열 추출, 냉침 추출, 환류냉각 추출, 또는 초음파 추출 등이 이용될 수 있으며, 당업자에게 자명한 추출법이라면 제한이 없다. 상기 추출은 실온에서 수행할 수도 있으나, 보다 효율적인 추출을 위해서는 가온 조건 하에서 수행할 수 있으며, 바람직하게는 약 40 내지 100℃, 더욱 바람직하게는 약 80℃의 온도에서 추출할 수 있으나, 이에 한정되는 것은 아니다. 추출시간은 바람직하게는 약 2 내지 4시간, 더욱 바람직하게는 약 3 시간 동안 수행할 수 있으나 이에 한정되는 것은 아니며, 추출 용매 및 추출 온도 등의 조건에 따라 달라질 수 있다. 상기 추출은 활성성분을 보다 다량 수득하기 위해 1 회 이상 여러 번 추출할 수 있으며, 바람직하게는 1 내지 5회, 더욱 바람직하게는 3회 연속추출하여 합한 추출액을 이용할 수 있다.In the present specification, the edelweiss extract may be a crude extract of water, a C 1 -C 6 alcohol, and a solvent selected from the group consisting of a combination thereof. The C 1 -C 6 alcohol may be specifically methanol. When extracting the edelweiss with a solvent, it is preferable to extract by adding a solvent corresponding to about 5 to 15 times the edelweiss, specifically, it is preferable to extract by adding about 10 times the solvent, but is not limited thereto. The extraction may be a heat extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction, and the like, there is no limitation if the extraction is obvious to those skilled in the art. The extraction may be performed at room temperature, but for more efficient extraction, the extraction may be performed under heating conditions, preferably at about 40 to 100 ° C., more preferably at about 80 ° C., but is not limited thereto. It is not. The extraction time is preferably about 2 to 4 hours, more preferably about 3 hours, but is not limited thereto, and may vary depending on conditions such as extraction solvent and extraction temperature. The extraction may be extracted one or more times several times in order to obtain a larger amount of the active ingredient, preferably one to five times, more preferably three times the continuous extraction can be used combined extract.
본 명세서에서 에델바이스 추출물은 상기와 같이 에델바이스의 조추출물을 포함할 수 있고, 상기 조추출물을 극성이 낮은 유기 용매로 더욱 추출하여 얻어진 유기 용매의 가용성 분획물로서 포함할 수도 있다. 상기 유기 용매로는 헥산, 메틸렌클로라이드, 에틸 아세테이트, n-부탄올 등이 이용될 수 있으나, 이에 한정되는 것은 아니다. 상기의 방법으로 추출한 추출물 또는 그 추출물의 가용성 분획물은 그대로 사용할 수도 있으나, 여과 후 농축하여 엑기스 형태로 사용할 수 있으며, 농축 후 동결 건조하여 동결건조물의 형태로서 사용할 수 있다. In the present specification, the edelweiss extract may include the crude extract of edelweis as described above, and may include the crude extract as a soluble fraction of the organic solvent obtained by further extracting the organic extract with a low polarity organic solvent. Hexane, methylene chloride, ethyl acetate, n-butanol, and the like may be used as the organic solvent, but is not limited thereto. The extract extracted by the above method or a soluble fraction of the extract may be used as it is, but may be used in the form of an extract by concentrating after filtration, it may be used as a lyophilized form by lyophilization after concentration.
본 명세서에서 "피부"라 함은, 동물의 체표를 덮는 조직을 의미하는 것으로서, 얼굴 또는 바디 등의 체표를 덮는 조직뿐만 아니라, 두피를 포함하는 광범위한 개념이다. As used herein, the term "skin" refers to a tissue covering the body surface of an animal, and is a broad concept including not only tissues covering the body surface such as the face or body, but also the scalp.
본 명세서에서 "피부 재생을 촉진"한다는 것은 새로운 피부세포의 형성을 촉진하고 노화된 피부의 각질탈락을 촉진시킴을 의미할 수 있고, 정상적인 피부세포 또는 상처가 있는 피부세포 모두의 재생을 포함한다. "Promoting skin regeneration" herein may mean promoting the formation of new skin cells and promoting exfoliation of aged skin and includes regeneration of both normal skin cells or wounded skin cells.
본 명세서에서 "모발"은 체모(體毛)와 두발(頭髮)을 총칭하는 것으로 헤어(hair)로도 기재될 수 있다. 상기 모발은 사람 및 동물의 것을 모두 포함한다.As used herein, "hair" may be described as hair as a general term for body hair and hair. The hair includes both human and animal hair.
본 명세서에서 "양모 촉진"은 새로운 모발의 생성을 촉진하는 것뿐만 아니라 기존 모발이 굵고 건강하게 자라도록 하는 것을 의미한다. As used herein, "promoting wool" means not only promoting the production of new hair, but also allowing existing hair to grow thick and healthy.
본 발명은 일 관점에서, 효소 처리 에델바이스의 추출물을 유효성분으로 포함하는 피부 재생 촉진제에 관한 것이다. In one aspect, the present invention relates to a skin regeneration accelerator comprising an extract of an enzyme-treated edelweiss as an active ingredient.
본 명세서에서 "효소"는 에델바이스를 구성하는 물질을 물리적 또는 화학적으로 변형시켜 이를 추출하였을 때, 고함량의 추출물을 얻을 수 있는 물질을 총칭한다. As used herein, the term "enzyme" refers to a substance which is capable of obtaining a high content of an extract when the substance constituting the edelweiss is extracted by physically or chemically modifying the substance.
본 발명의 일 관점에 있어서, 상기 효소는 식물의 유효성분을 고함량, 고수들률로 얻을 수 있도록 하는 효소이면 제한이 없으며, 구체적으로, 세포벽 분해효소를 포함한다. In one aspect of the present invention, the enzyme is not limited so long as it is an enzyme capable of obtaining an active ingredient of a plant at a high content and high yield rate, and specifically, includes a cell wall degrading enzyme.
본 명세서에서 "세포벽 분해효소 (cell wall degradation enzyme)"는 식물 세포벽의 분해에 관여하는 효소를 의미할 수 있다. 세포벽은 일반적으로, 셀룰로오스, 헤미셀룰로오스, 펙틴물질, 리그닌, 단백질, 마그네슘, 칼슘 등으로 구성되어 있다. 셀룰로오스 분해효소로는 엑소-β,4 글루카나아제(섬유소분해효소 C1), 엔도-β,4 글루카나아제(섬유소분해효소 Cx); 헤미셀룰로오스 분해효소로서는 크실라나아제, 1,3-크실라나아제, α-L-아르비노푸라노시다아제 등이 있으며; 펙틴질분해효소에는 펙틴 및 펙틴산의 주사슬의 α-1,4결합을 절단하는 효소군(엔도-폴리메틸갈락투로나아제(endo-PMG), 엔도-폴리갈락투로나아제(endo-PG), 엔도-펙틴트랜스일리미나아제(endo-PTE), 엔도-폴리갈락투론산 트랜스-일리미나아제(endo-PATE), 엑소-폴리메틸갈락투로나아제(exo-PMG), 엑소-폴리갈락투로나아제(exo-PG), 엑소-펙틴트랜스일리미나아제(exo-PTE), 엑소-폴리갈락투론산 트랜스-일리미나아제(exo-PATE))과 펙틴의 메틸기를 유리하는 펙틴메틸에스테르가수분해효소가 있지만, 이에 제한되는 것은 아니다. As used herein, "cell wall degradation enzyme" may refer to an enzyme that is involved in degradation of the plant cell wall. The cell wall is generally composed of cellulose, hemicellulose, pectin substance, lignin, protein, magnesium, calcium and the like. Cellulolytic enzymes include exo-β, 4 glucanase (fibrinase C1), endo-β, 4 glucanase (fibrinase Cx); Hemicellulose degrading enzymes include xylanase, 1,3-xylanase, α-L-arbinofuranosidase, and the like; Pectinase is a group of enzymes that cleave α-1,4 bonds of the main chains of pectin and pectinic acid (endo-polymethylgalacturonase (endo-PMG), endo-polygalacturonase (endo-). PG), endo-pectintranslylimase (endo-PTE), endo-polygalacturonic acid trans-iriminase (endo-PATE), exo-polymethylgalacturonase (exo-PMG), exo- Pectin liberating the methyl group of polygalacturonase (exo-PG), exo-Pectintranslylimase (exo-PTE), exo-polygalacturonic acid trans-Iliaminase (exo-PATE) and pectin Methyl ester hydrolase, but is not limited thereto.
식물의 세포는 동물의 세포와 달리 단단한 세포벽으로 싸여있다. 세포벽은 생성 초기에는 펙틴과 셀룰로오스로 구성되나, 그 후 목화하여 셀룰로스 외에 많은 리그닌 및 헤미셀룰로오스를 함유하게 된다. 셀룰라아제는 셀룰로오스를 분해하는 효소로서 이를 처리하게 되면 단단한 세포벽이 일부 분해되면서 식물 내 유효 성분의 추출 효율이 높아지게 된다. 따라서 에델바이스 추출 전 셀룰라아제를 세포벽 분해효소와 반응시키면 효소를 처리하지 않은 경우에 비해 식물 세포 내 유효 성분 추출 효율이 높아져 원료의 효능 또한 증가할 수 있다. Plant cells, unlike animal cells, are wrapped in a rigid cell wall. The cell wall is composed of pectin and cellulose at the beginning, but is then cottoned to contain many lignin and hemicellulose in addition to cellulose. Cellulase is an enzyme that breaks down cellulose, and processing it increases the efficiency of extracting active ingredients from plants as the hard cell wall is partially broken down. Therefore, when the cellulase is reacted with the cell wall degrading enzyme before extraction of edelweiss, the efficiency of extracting the active ingredient in the plant cell may be increased as compared with the case where the enzyme is not treated, thereby increasing the efficacy of the raw material.
본 명세서에서 사용되는 에델바이스는 추출물의 형태로 포함되거나, 생약 자체의 분쇄물, 또는 생약의 건조 분쇄물로서 포함될 수 있으나, 이에 제한되는 것은 아니다. 아울러 본 명세서에서 사용되는 에델바이스는 그 입수 방법에 제한이 없으며, 재배하여 사용하거나 시판되는 것을 구입하여 사용할 수도 있으며, 초본의 지상부의 일부 또는 전부를 사용할 수 있으며, 바람직하게는 지상부의 전부를 사용할 수 있다. As used herein, edelweiss may be included in the form of an extract, or may be included as a ground powder of the herbal medicine, or as a dry ground powder of the herbal medicine, but is not limited thereto. In addition, the edelweiss used in the present specification is not limited to the method of acquiring, can also be grown and used or purchased commercially available, can use some or all of the above-ground parts of the herb, preferably all of the above-ground parts can be used have.
본 명세서에서 "효소처리 에델바이스 추출물"은 에델바이스에 세포벽 분해효소를 처리한 후, 이를 추출하여 얻어질 수 있다. In the present specification, "enzyme-treated edelweiss extract" may be obtained by treating cell edase on edelweis and extracting it.
본 명세서에서 효소 처리 에델바이스 추출물은 에델바이스 추출물은 에델바이스를 세척하고 건조하는 단계; 에델바이스에 효소를 처리하는 단계; 에델바이스를 용매 추출하는 단계; 및 추출한 에델바이스를 여과하는 단계를 거쳐 수득할 수 있다. 상기에서 용매는 물, 유기 용매 및 물과 유기 용매의 혼합물로 이루어진 군에서 선택된 하나 이상을 포함한다. 상기에서 물은 증류수 또는 정제수를 포함하고, 유기 용매는 C1~C5의 저급 알코올을 예로 들 수 있는 알코올, 아세톤, 에테르, 에틸아세테이트, 디에틸에테르, 에틸메틸케톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상을 포함하나, 이에 제한되는 것은 아니다.In the present specification, the enzyme-treated edelweiss extract, the edelweiss extract, washing and drying the edelweiss; Treating the enzyme with edelweiss; Solvent extraction of edelweiss; And it can be obtained through the step of filtering the extracted edelweiss. In the above, the solvent includes at least one selected from the group consisting of water, an organic solvent, and a mixture of water and an organic solvent. In the above, water includes distilled water or purified water, and the organic solvent is selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform, for example, a lower alcohol having 1 to 5 carbon atoms. Including but not limited to one or more.
본 발명의 일 관점인 촉진제에 있어서, 상기 효소는 셀룰라아제 (cellulase), 크실라나아제 (xylanase) 및 아라비노푸라노시다아제 (arabinofuranosidase)로 이루어진 군에서 선택될 수 있다.In one embodiment of the present invention, the enzyme may be selected from the group consisting of cellulase, xylanase, and arabinofuranosidase.
본 발명의 일 관점인 촉진제에 있어서, 상기 추출물은 세포벽 분해효소를 에델바이스 총중량에 대하여 0.01 내지 1중량%로 첨가하여 얻어질 수 있다.In one aspect of the present invention, the extract may be obtained by adding 0.01 to 1% by weight of the cell wall degrading enzyme relative to the total weight of the edelweiss.
상기 세포벽 분해효소는 에델바이스 총중량에 대하여 0.001 내지 10중량%로 함유될 수 있다. 세포벽 분해효소가 0.001중량%미만으로 함유되면, 에델바이스 추출물에 포함되는 유효성분인 클로로겐산의 함량증가가 미미하며, 10중량%를 초과하여 함유되면, 세포벽 분해 효소의 함량으로 다른 구성 성분의 함량을 제한하게 된다. 상기와 같은 관점에 있어서, 에델바이스 추출물은 조성물 전체 중량에 대하여, 0.0011 내지 9중량%, 0.0012 내지 8중량%, 0.0013 내지 7중량%, 0.0014 내지 6중량%, 0.0015 내지 5중량%, 0.0016 내지 4중량%, 0.0017 내지 3중량%, 0.0018 내지 2중량% 또는 0.0019 내지 1중량%으로 함유될 수 있다.The cell wall degrading enzyme may be contained in 0.001 to 10% by weight relative to the total weight of the edelweiss. If the cell wall degrading enzyme is contained in less than 0.001% by weight, the increase in the content of chlorogenic acid, an active ingredient included in the edelweiss extract is insignificant, and if it contains more than 10% by weight, the content of other components is limited by the content of the cell wall degrading enzyme Done. In view of the above, the edelweiss extract is 0.0011 to 9% by weight, 0.0012 to 8% by weight, 0.0013 to 7% by weight, 0.0014 to 6% by weight, 0.0015 to 5% by weight, 0.0016 to 4% by weight based on the total weight of the composition %, 0.0017 to 3% by weight, 0.0018 to 2% by weight or 0.0019 to 1% by weight.
본 발명의 일 관점인 촉진제에 있어서, 효소처리 에델바이스 추출물은 클로로겐산 (chlorogenic acid)을 6ppm이상 포함할 수 있다. 이와 같은 범위의 클로로겐을 포함하는 경우, 효소 처리하지 않는 에델바이스 추출물보다 우수한 피부 재생, 모발 성장 촉진 효능을 가질 수 있다. 이러한 관점에서, 본 명세서의 세포벽 분해 효소를 처리한 에델바이스로부터 얻어지는 추출물은 유효성분인 클로로겐산을 전체 추출물 중량에 대하여, 6.5ppm이상, 7ppm이상, 7.5ppm이상, 8ppm이상, 8.5ppm이상, 9ppm이상, 9.5ppm이상, 10ppm이상, 10.5ppm이상, 11ppm이상 또는 11.5ppm이상 포함할 수 있으며, 100,000ppm이하 또는 10,000ppm이하로 포함할 수 있다. In one aspect of the present invention, the enzyme-treated edelweiss extract may contain 6 ppm or more of chlorogenic acid. In the case of containing such a range of chlorogen, it can have a better skin regeneration, hair growth promoting effect than the edelweiss extract without enzyme treatment. In view of this, the extract obtained from the edelweiss treated with the cell wall degrading enzyme of the present specification is at least 6.5ppm, at least 7ppm, at least 7.5ppm, at least 8ppm, at least 8.5ppm, at least 9ppm, based on the total extract weight of chlorogenic acid as an active ingredient. It may include more than 9.5ppm, more than 10ppm, more than 10.5ppm, more than 11ppm or more than 11.5ppm, may contain less than 100,000ppm or less than 10,000ppm.
본 발명의 일측면에 따른 촉진제는 촉진제 전체 중량을 기초로 0.01 중량% 내지 10 중량%, 구체적으로 0.1 중량% 내지 5 중량%, 더 구체적으로 0.5 중량% 내지 3 중량%의 에델바이스 추출물을 포함할 수 있다. 상기 범위로 포함할 경우 본 발명의 의도한 효과를 나타내기에 적절할 뿐만 아니라, 조성물의 안정성 및 안전성을 모두 만족할 수 있으며, 비용 대비 효과의 측면에서도 상기 범위로 포함하는 것이 적절할 수 있다. 구체적으로 에델바이스 추출물이 0.01 중량% 미만인 경우 충분한 피부 재생 및 모발 성장 촉진 효과를 얻을 수 없고, 10 중량%를 초과하는 경우 안전성 및 제형 안정성이 낮아질 수 있다.Accelerators according to one aspect of the invention may comprise from 0.01% to 10% by weight, specifically from 0.1% to 5% by weight, more specifically from 0.5% to 3% by weight, based on the total weight of the accelerator. have. When included in the above range is not only suitable for showing the intended effect of the present invention, it can satisfy both the stability and safety of the composition, it may be appropriate to include in the above range in terms of cost-effectiveness. Specifically, when the edelweiss extract is less than 0.01% by weight, sufficient skin regeneration and hair growth promoting effect may not be obtained, and when it exceeds 10% by weight, safety and formulation stability may be lowered.
본 발명은 다른 관점에서, 에델바이스 추출물을 포함하는 화장료 조성물에 관한 것이다. 상기 화장료 조성물은 피부 재생 효과를 가지며, 구체적으로 상처를 치유하고 흉터를 감소시킬 수 있다. 또한 상기 화장료 조성물은 모발 성장을 촉진하며, 나아가 탈모를 방지하고 양모를 촉진할 수 있다. In another aspect, the present invention relates to a cosmetic composition comprising the edelweiss extract. The cosmetic composition has a skin regeneration effect, specifically it can heal wounds and reduce scars. In addition, the cosmetic composition may promote hair growth, further prevent hair loss and promote wool.
본 발명에 따른 화장료 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있다. 예를 들면, 용액, 수상에 유상을 분산시켜 얻은 에멀젼, 유상에 수상을 분산시켜 얻은 에멀젼, 현탁액, 고체, 겔, 분말, 페이스트, 마이크로 니들, 포말(foam) 또는 에어로졸 조성물의 제형으로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.Cosmetic compositions according to the invention may be provided in all formulations suitable for topical application. For example, it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a microneedle, a foam, or an aerosol composition. have. Compositions of such formulations may be prepared according to conventional methods in the art.
본 발명에 따른 화장료 조성물은 상기한 물질 이외에 주 효과를 손상시키지 않는 범위 내에서, 바람직하게는 주 효과에 상승 효과를 줄 수 있는 다른 성분들을 포함할 수 있다. 또한 본 발명에 따른 화장료 조성물은 보습제, 에몰리언트제, 계면 활성제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 냉감제 또는 제한제를 더 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 전체 중량을 기준으로 0.01 내지 5 중량%, 구체적으로 0.01 내지 3 중량%일 수 있다.The cosmetic composition according to the present invention may include other ingredients in addition to the above-mentioned substances within the range not impairing the main effect, preferably giving a synergistic effect to the main effect. In addition, the cosmetic composition according to the present invention may further include a moisturizer, an emulsifier, a surfactant, a ultraviolet absorber, a preservative, a bactericide, an antioxidant, a pH adjuster, an organic and an inorganic pigment, a perfume, a cooling agent, or a restricting agent. The blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition have.
본 발명은 다른 관점에서, 에델바이스 추출물을 포함하는 약학 조성물에 관한 것이다. 상기 약학 조성물은 피부 재생 효과를 가지며, 구체적으로 상처를 치유하고 흉터를 감소시킬 수 있다. 또한 상기 약학 조성물은 모발 성장을 촉진하며, 나아가 탈모를 방지하고 양모를 촉진할 수 있다.In another aspect, the present invention relates to a pharmaceutical composition comprising the edelweiss extract. The pharmaceutical composition has a skin regenerating effect, and may specifically heal wounds and reduce scars. In addition, the pharmaceutical composition may promote hair growth, further prevent hair loss and promote wool.
본 발명의 일측면에 따른 약학 조성물은 경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다.The pharmaceutical composition according to one aspect of the present invention may be administered orally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously, and the like.
경구 투여를 위한 제형은 정제, 환제, 연질 및 경질 캅셀제, 과립제, 산제, 세립제, 액제, 유탁제 또는 펠렛제일 수 있으나, 이에 제한되는 것은 아니다. 이들 제형은 유효 성분 이외에 희석제(예: 락토오스, 덱스트로오스, 수크로오스, 만니톨, 솔비톨, 셀룰로오스 또는 글리신), 활택제(예: 실리카, 탈크, 스테아르산 또는 폴리에틸렌 글리콜), 또는 결합제(예: 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로오스, 나트륨 카르복시메틸셀룰로오스 또는 폴리비닐피롤리딘)를 함유할 수 있다. 경우에 따라 붕해제, 흡수제, 착색제, 향미제, 또는 감미제 등의 약제학적 첨가제를 함유할 수 있다. 상기 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.Formulations for oral administration may be, but are not limited to, tablets, pills, soft and hard capsules, granules, powders, granules, solutions, emulsions or pellets. These formulations may contain, in addition to the active ingredient, diluents (e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine), glidants (e.g. silica, talc, stearic acid or polyethylene glycol), or binders (e.g. magnesium aluminum Silicates, starch pastes, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpyrrolidine). It may optionally contain pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, or sweeteners. The tablets can be prepared by conventional mixing, granulating or coating methods.
비경구 투여를 위한 제제는 주사제, 점적제, 로션, 연고, 겔, 크림, 현탁제, 유제, 좌제, 패취 또는 분무제일 수 있으나, 이에 제한되는 것은 아니다.Formulations for parenteral administration may be, but are not limited to, injections, drops, lotions, ointments, gels, creams, suspensions, emulsions, suppositories, patches or sprays.
본 발명의 일측면에 따른 약학 조성물의 유효 성분은 투여받을 대상의 연령, 성별, 체중, 병리 상태 및 그 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 적용량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1mg/kg/일 내지 100mg/kg/일, 보다 구체적으로는 5 mg/kg/일 내지 50 mg/kg/일이 될 수 있으나, 이에 제한되는 것은 아니다.The active ingredient of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Dosage determination based on these factors is within the level of one skilled in the art and its daily dosage may be, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / kg. May be, but is not limited to.
본 발명은 다른 관점에서, 에델바이스 추출물을 포함하는 건강식품 조성물에 관한 것이다. 상기 식품 조성물은 피부 재생 효과를 가지며, 구체적으로 상처를 치유하고 흉터를 감소시킬 수 있다. 또한 상기 식품 조성물은 모발 성장을 촉진하며, 나아가 탈모를 방지하고 양모를 촉진할 수 있다. In another aspect, the present invention relates to a health food composition comprising an edelweiss extract. The food composition has a skin regenerating effect, and may specifically heal wounds and reduce scars. In addition, the food composition may promote hair growth, further prevent hair loss and promote wool.
상기 식품 조성물의 제형은 특별히 한정되지 않으나, 예를 들어, 정제, 과립제, 분말제, 드링크제와 같은 액제, 캐러멜, 겔, 바 등으로 제형화될 수 있다. 각 제형의 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.The formulation of the food composition is not particularly limited, but may be, for example, formulated into a liquid such as tablets, granules, powders, drinks, caramels, gels, bars, and the like. In addition to the active ingredient, the food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials.
상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1mg/kg/일 내지 5000mg/kg/일, 보다 구체적으로는 50 mg/kg/일 내지 500 mg/kg/일이 될 수 있으나, 이에 제한되지 않으며, 투여하고자 하는 대상의 연령, 건강 상태, 합병증 등 다양한 요인에 따라 달라질 수 있다.Determination of the dosage of the active ingredient is within the level of those skilled in the art, the daily dosage of which is for example from 0.1 mg / kg / day to 5000 mg / kg / day, more specifically from 50 mg / kg / day to 500 mg / kg / day, but is not limited thereto, and may vary depending on various factors such as age, health condition, and complications of the subject to be administered.
이하, 실시예 및 시험예를 들어 본 발명의 구성 및 효과를 보다 구체적으로 설명한다. 그러나, 이들 실시예 및 시험예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 발명의 범주 및 범위가 그에 의해 제한되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to Examples and Test Examples. However, these examples and test examples are provided only for the purpose of illustration in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited thereto.
[실시예 1] 에델바이스 추출물의 제조Example 1 Preparation of Edelweiss Extract
에델바이스(Leontopoium alpinum)를 초정제수로 세척하여 250 메쉬(mesh) 필터에 걸러 50℃에서 24시간 동안 건조한다. 건조한 에델바이스 1kg에 20L의 증류수를 첨가하고 4℃의 온도 조건 하에서 48시간 동안 추출한다. 그 후 250 메쉬 필터에 걸러 침전 시킨 후 다시 한번 0.5μm 필터에 거른다. 활성 탄소로 탈색, 탈취 과정을 거쳐 0.5μm 필터에 걸러 에델바이스 추출물을 수득한다.Edelweiss ( Leontopoium alpinum ) was washed with ultrapure water and filtered over a 250 mesh filter and dried at 50 ° C for 24 hours. 20 L of distilled water is added to 1 kg of dry edelweiss and extracted for 48 hours under a temperature condition of 4 ° C. After that, the precipitate is filtered through a 250 mesh filter, and then again filtered through a 0.5 μm filter. After decolorization and deodorization with activated carbon, the edelweiss extract is obtained by filtration through a 0.5 μm filter.
[실시예 2] 효소 처리한 에델바이스의 추출물 제조Example 2 Preparation of Extract of Edelweiss Treated with Enzyme
에델바이스(Leontopoium alpinum)를 초정제수로 세척하여 250 메쉬(mesh) 필터에 걸러 50℃에서 24시간 동안 건조한다. 건조한 에델바이스 1kg에 2L의 증류수를 첨가하고 여기에 셀룰라아제 100g을 첨가하여 pH를 4.8로 조정한다. 효소반응 온도인 40℃에서 72시간 반응시킨다. 이후 18L의 증류수를 첨가하고 4℃의 온도 조건 하에서 48시간 동안 추출한다. 그 후 250 메쉬 필터에 걸러 침전 시킨 후 다시 한번 3μm 필터에 거른다. 활성 탄소로 탈색, 탈취 과정을 거쳐 0.5μm 필터에 걸러 에델바이스 추출물을 수득한다.Edelweiss ( Leontopoium alpinum ) was washed with ultrapure water and filtered over a 250 mesh filter and dried at 50 ° C for 24 hours. To 1 kg of dry Edelweiss, 2 L of distilled water is added and 100 g of cellulase is added to adjust the pH to 4.8. The reaction is carried out at 40 ° C. for 72 hours. Then 18 L of distilled water is added and extracted for 48 hours under the temperature condition of 4 ℃. After that, it is filtered through a 250 mesh filter and once again filtered through a 3μm filter. After decolorization and deodorization with activated carbon, the edelweiss extract is obtained by filtration through a 0.5 μm filter.
[시험예 1] 줄기세포의 윈트/베타 카테닌 신호 전달 촉진 효과 평가Test Example 1 Evaluation of the Wint / Betacatenin Signal Transduction Promoting Effect of Stem Cells
줄기세포에 Wnt 신호가 주어지면 세포 내 베타-카테닌(beta-catenin)을 억제하고 있는 단백질 복합체(GSK3, APC, Axin)가 저해되면서 베타-카테닌이 세포 핵 내로 이동하고 발생 및 모발 성장에 관여하는 다양한 유전자가 발현된다.When Wnt signals are given to stem cells, protein complexes (GSK3, APC and Axin) that inhibit intracellular beta-catenin are inhibited and beta-catenin moves into the cell nucleus and is involved in development and hair growth. Various genes are expressed.
베타-카테닌은 전사 조절인자로서 염색체의 특정 염기 서열에 부착하는데, 이러한 베타-카테닌 부착 염기 서열 뒤에 가우시아 루시퍼라제(Gaussia luciferase) 유전자 염기 서열을 인위로 조합한 플라스미드 벡터를 제작하여 HEK293(인간 배아 신장 세포주)에 트랜스펙션(transfection)한다. 이렇게 제작한 형질전환 세포주는 G418 항생제에 저항성이 있어, G418이 포함된 배지에 배양할 경우 형질전환 세포주만 선택적으로 배양이 가능하다. 이와 같이 수득한 윈트/베타 카테닌 신호 전달 체계를 보유한 형질전환 HEK293 세포주에 실시예의 에델바이스 추출물을 처리한 후 가우시아 루시퍼라제 분석 키트(Gaussia luciferase assay kit, BioLabs)로 가우시아 루시퍼라제의 발현 증가 여부를 확인하였다.Beta-catenin is a transcriptional regulator attached to a specific nucleotide sequence of the chromosome, and a plasmid vector obtained by artificially combining the beta-catenin attachment nucleotide sequence followed by a Gaussian luciferase gene sequence is prepared for HEK293 (human embryos). Renal cell line). The transformed cell line thus prepared is resistant to G418 antibiotics, and when cultured in a medium containing G418, only the transformed cell line can be selectively cultured. The transformed HEK293 cell line having the Wint / Beta catenin signal transduction system thus obtained was treated with the Edelweiss extract of Example, and then Gaussian luciferase assay kit (BioLabs) increased the expression of Gaussian luciferase. Confirmed.
구체적으로, 형질전환 HEK293 세포를 10% 소혈청 세럼(Fetal bovine serum) (FBS)과 G418 500μg/ml이 함유된 Dulbecco's modified Eagle's medium(DMEM; Gibco BRL, Gaithersburg, MD, USA)로 5% CO2, 37℃의 인큐베이터에서 24시간 동안 배양하였다. 96-웰 플레이트에서 24시간 동안 배양한 세포에 각각 실시예 1의 2 ppm 및 5 ppm의 에델바이스 추출물과 실시예 2의 2ppm 및 5ppm의 효소처리 에델바이스 추출물을 처리한 후 다시 48시간 동안 인큐베이터에서 배양하였다. 양성 대조군으로는 글리코겐 신타제 키나제 3-β(glycogen synthase kinase 3 beta, GSK-3β) 저해제로 널리 사용되고 있는 소듐 발프론산(Sodium valproic acid, VPA) 16.6 ppm, 50 ppm 및 83 ppm을 사용하였다. 가우시아 루시퍼라제 분석 키트를 이용하여 배양한 세포의 루시퍼라제 발현 정도를 측정하여 에델바이스 추출물이 윈트/베타 카테닌 신호 전달에 미치는 효과를 평가하였다. 그 결과를 도 1 및 도 5에 나타내었다. Specifically, the transgenic HEK293 cells, 10% bovine serum serum (Fetal bovine serum) (FBS) and G418 500μg / Dulbecco's modified Eagle's medium with ml containing; a (DMEM Gibco BRL, Gaithersburg, MD , USA) 5% CO 2 Incubated for 24 hours in an incubator at 37 ℃. Cells cultured in 96-well plates for 24 hours were treated with 2 ppm and 5 ppm of edelweiss extract of Example 1 and 2ppm and 5ppm of enzyme-treated edelweiss extract of Example 2, respectively, and then cultured in an incubator for 48 hours. . As a positive control, 16.6 ppm, 50 ppm and 83 ppm of sodium valproic acid (VPA), which is widely used as a glycogen synthase kinase 3-beta (GSK-3β) inhibitor, were used. Luciferase expression levels of the cultured cells were measured using a Gaussian luciferase assay kit to evaluate the effect of Edelweiss extract on wint / beta catenin signal transduction. The results are shown in FIGS. 1 and 5.
도 1에서 볼 수 있듯이, 에델바이스 추출물은 줄기세포의 윈트/베타 카테닌 신호 전달을 촉진한다. 이를 통해 에델바이스 추출물은 피부 재생 및 모발 성장을 촉진하는 효과를 가짐을 알 수 있다.As can be seen in Figure 1, the edelweiss extract promotes the wint / beta catenin signal transduction of stem cells. It can be seen that the edelweiss extract has the effect of promoting skin regeneration and hair growth.
또한 도 5에서 볼 수 있듯이, 에델바이스 추출물 및 효소처리 에델바이스 추출물은 줄기세포의 윈트/베타 카테닌 신호 전달을 촉진하며, 효소처리 에델바이스 추출물이 일반 에델바이스 추출물보다 효과가 좋은 것을 볼 수 있다. 본 결과를 통해 셀룰라아제 효소를 처리함으로써 에델바이스 추출물의 피부 재생 및 모발 성장 촉진 효과를 증가시킬 수 있음 알 수 있었다.In addition, as shown in Figure 5, the edelweiss extract and the enzyme-treated edelweiss extract promotes the wint / beta catenin signal transmission of stem cells, it can be seen that the enzyme-treated edelweiss extract is better than the general edelweiss extract. The results show that the treatment of cellulase enzyme can increase the skin regeneration and hair growth promoting effect of the edelweiss extract.
[시험예 2] 알카라인 포스파타아제 활성능 평가Test Example 2 Evaluation of Alkaline Phosphatase Activity
에델바이스 추출물이 인간 모유두 세포주의 줄기세포성을 유지시킬 수 있는지 여부를 평가하기 위해, 생체 외(in vitro) 시스템을 적용하여 에델바이스 추출물 적용 후 세포주의 줄기세포성 유지와 관련있는 알카라인 포스파타아제 효소의 활성을 평가하였다.In order to evaluate whether Edelweiss extract can maintain the stem cellularity of human dermal papilla cell lines, we applied an in vitro system to determine the alkaline phosphatase enzymes involved in maintaining the stem cell lines after application of Edelweiss extract. Activity was evaluated.
상기 평가를 위해 인간 모유두 세포(Human dermal papilla cell)를 Simian virus 40 large T(SV40T)와 c-myc를 포함하는 벡터로 형질 도입(transduction)하여 제조한 불멸화된 모유두 세포인 iDPc(Human immortalized dermal papilla cell)를 사용하였다. 상기 세포주를 10% 소혈청 세럼(FBS)이 함유된 Dulbecco's modified Eagle's medium(DMEM; Gibco BRL, Gaithersburg, MD, USA)로 5% CO2, 37℃의 인큐베이터에서 24시간 동안 배양한 후 각각 실시예 1의 10ppm 및 20ppm의 에델바이스 추출물을 처리하였다. 음성 대조군으로는 DMSO를 사용하였으며, 양성 대조군으로는 글리코겐 신타제 키나제 3-β(glycogen synthase kinase 3 beta, GSK-3β) 저해제로 널리 사용되고 있는 소듐 발프론산(Sodium valproic acid, VPA) 83 ppm과 166 ppm을 사용하였다. 시험 물질을 처리하고 48시간 후 세포들을 얼음 위에서 PBS 생리식염수(Phosphate buffered saline)로 2회 세척한 다음, 세포 위에 300μl ALP 분석 버퍼(ALP assay kit, BioVision, Catalog #K412-500)를 넣고 스크래퍼로 긁어 에펜도르프 튜브(eppendorf tube)에 모았다. 모은 세포들을 얼음 위에서 프로브 소니케이터(probe sonicator)로 깨어, 4℃, 12,000 rpm에 5분 동안 원심 분리하고 상층액을 취하였다. 로우리법(Lowry's method)를 기본으로 한 바이오-라드 DC 단백질 키트(Bio-rad DC protein kit)(Biorad, cat.no. 500-0111)를 사용하여 제조자의 권장 방법에 따라, 상층액에 포함된 세포 단백질의 농도를 측정하였다. 측정한 농도 값을 환산하여 시험 물질의 알카라인 포스파타아제 활성을 평가하였다.Human immortalized dermal papilla, iDPc, is an immortalized dermal papilla cell prepared by transducing human dermal papilla cells with a vector containing Simian virus 40 large T (SV40T) and c-myc. cell) was used. The cell lines were incubated for 24 hours in an incubator at 5% CO 2 , 37 ° C. in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) containing 10% bovine serum serum (FBS), respectively. 10 ppm and 20 ppm edelweiss extracts of 1 were treated. DMSO was used as a negative control, and 83 ppm of sodium valproic acid (VPA), which is widely used as a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, was used as a positive control. 166 ppm was used. After 48 hours of treatment with the test material, the cells were washed twice with PBS Phosphate buffered saline on ice, and then 300 μl ALP assay buffer (ALP assay kit, BioVision, Catalog # K412-500) was placed on the cells and scraped. The scrapes were collected in eppendorf tubes. The collected cells were awakened on a probe sonicator on ice, centrifuged at 4 ° C., 12,000 rpm for 5 minutes, and the supernatant was taken. Using the Bio-rad DC protein kit (Biorad, cat.no. 500-0111) based on Lowry's method, included in the supernatant according to the manufacturer's recommended method The concentration of cellular protein was measured. The alkaline phosphatase activity of the test substance was evaluated in terms of the measured concentration values.
구체적으로, 알카라인 포스파타아제 효소의 기질인 니트로페닐 포스페이트(nitrophnyl phosphate, pNPP)를 pNPP tab(ALP assay kit, BioVision, Catalog #K412-500) 분석 버퍼에 녹여 5mM 농도로 준비하고 세포 단백질과 반응하도록 넣어주었다. 1mM 농도로 녹인 pNPP를 4 ~ 20 ㎕까지 농도 별로 넣고, ALP 효소를 넣어 pNPP의 효소 분해 반응이 일어나도록 하여 표준액을 준비하였다. 위의 효소 반응이 일어나도록 시험 물질과 표준액이 든 96-웰 플레이트를 25℃ 배양기에 1시간 동안 넣어준 다음, 정지 용액(stop solution)을 넣고, 405nm에서 흡광도를 측정하여 pNPP가 효소 반응에 의해 분해되어 생성되는 pNP의 양으로 효소의 활성 값을 구하였다. 그 결과를 도 2에 나타내었다.Specifically, nitrophenyl phosphate (pNPP), which is a substrate of alkaline phosphatase enzyme, is dissolved in pNPP tab (ALP assay kit, BioVision, Catalog # K412-500) assay buffer, prepared at a concentration of 5 mM, and reacted with cellular proteins. Put it. The pNPP dissolved in 1mM concentration was added to 4 ~ 20 농도 by concentration, and the standard solution was prepared by adding an ALP enzyme to cause the enzymatic degradation reaction of pNPP. In order to cause the above enzymatic reaction, a 96-well plate containing test material and standard solution was placed in a 25 ° C. incubator for 1 hour, and then, a stop solution was added, and the absorbance was measured at 405 nm. The activity value of the enzyme was determined by the amount of pNP produced by degradation. The results are shown in FIG.
도 2에서 볼 수 있듯이, 에델바이스 추출물은 모유두 세포 내의 알카라인 포스파타아제 활성능을 증가시켰다. 즉, 에델바이스 추출물은 모유두 세포주의 줄기세포성을 유지 및 활성화시켜 모발 생성을 촉진할 수 있음을 알 수 있다.As can be seen in Figure 2, the edelweiss extract increased the alkaline phosphatase activity in the dermal papilla cells. In other words, it can be seen that the edelweiss extract can promote hair production by maintaining and activating the stem cell nature of the dermal papilla cell line.
[시험예 3] 모낭 모유두 세포 증식 효과 평가Test Example 3 Evaluation of hair follicle papilla cell proliferation effect
모발을 구성하는 케라틴 단백질은 모근부 케라틴형성세포(keratinocyte)에서 생성되며, 이 케라틴형성세포는 모유두 세포로부터 분화된다. 따라서 에델바이스 추출물이 모유두 세포의 활성을 촉진한다면 그로부터 분화되는 케라틴형성세포의 활성을 촉진시킬 수 있고, 나아가 모발 생성을 촉진할 수 있을 것이다.The keratin proteins that make up hair are produced in hair root keratinocytes, which are differentiated from dermal papilla cells. Therefore, if the edelweiss extract promotes the activity of the dermal papilla cells, it may promote the activity of keratinocytes differentiated therefrom and further promote hair production.
에델바이스 추출물의 모유두 세포 활성 촉진 효과를 평가하기 위하여 본 발명에서는 iDPc(Human immortalized dermal papilla cell) 세포주를 사용하였다. 본 세포주는 사람 모유두 세포(Human dermal papilla cell)를 Simian virus 40 large T(SV40T)와 c-myc를 포함하는 벡터로 형질 도입(transduction)하여 제조한 불멸화된 모유두 세포이다. 상기 세포주는 10% 소혈청세럼(FBS)이 함유된 Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA)로 5% CO2, 37℃가 유지되는 인큐베이터에서 24시간 동안 배양한 후 각각 실시예1의 2ppm 및 5ppm의 에델바이스 추출물과 실시예 2의 2ppm 및 5ppm의 효소처리 에델바이스 추출물을 처리하였다. 음성 대조군으로는 DMSO를 사용하였다. 시험 물질 처리 24시간 경과 후에 WST-1 키트(Roche)을 사용하여 세포 증식능(%)을 측정하였다. 그 결과를 도 3 및 도 6에 나타내었다.In order to evaluate the effect of promoting the dermal papilla cell activity of the edelweiss extract, iDPc (Human immortalized dermal papilla cell) cell line was used. The cell line is an immortalized papillary cell prepared by transducing human dermal papilla cells with a vector containing Simian virus 40 large T (SV40T) and c-myc. The cell lines were incubated for 24 hours in an incubator maintained at 5% CO 2 , 37 ° C. in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) containing 10% bovine serum serum (FBS). The 2ppm and 5ppm edelweiss extracts of Example 1 and the 2ppm and 5ppm enzymatically treated edelweiss extracts of Example 2 were treated. DMSO was used as a negative control. 24 hours after the test material treatment, the cell proliferation (%) was measured using the WST-1 kit (Roche). The results are shown in FIGS. 3 and 6.
도 3에서 볼 수 있듯이, 에델바이스 추출물은 모유두 세포의 증식을 유의차 있게 증가시켰다. 이를 통해 에델바이스 추출물은 모유두 세포의 증식을 촉진시키고, 나아가 케라틴형성세포의 활성 및 모발 생성을 촉진할 수 있음을 알 수 있다.As can be seen in Figure 3, the edelweiss extract significantly increased the proliferation of dermal papilla cells. It can be seen that the edelweiss extract may promote the growth of dermal papilla cells, and further promote the activity and hair production of keratinocytes.
도 6에서 볼 수 있듯이, 효소처리 에델바이스 추출물은 효소처리 전에 비해 모유두 세포의 증식을 증가시켰다. 이를 통해 효소처리 에델바이스 추출물은 모유두 세포의 증식을 촉진시키고, 나아가 케라틴형성세포의 활성 및 모발 생성을 촉진할 수 있음을 알 수 있다.As can be seen in Figure 6, the enzyme treated edelweiss extract increased the growth of dermal papilla cells compared to before the enzyme treatment. It can be seen that the enzyme-treated edelweiss extract can promote the growth of dermal papilla cells and further promote the activity and hair production of keratinocytes.
[시험예 4] 인체 모낭기관을 이용한 모발 성장 촉진 효과 평가Test Example 4 Evaluation of Hair Growth Promoting Effect Using Human Hair Follicle Organs
55세 남성의 후두부 두피조직으로부터 모낭 기관을 하나씩 분리하여 William's E 배지(L-glutamine(2mM), insulin(10㎍/ml), hydrocortisone(40ng/ml), antibiotics(1%), fungizon(1%) 함유)에 배양하였다. 배양 후 3일째에 성장이 일어난 모낭을 선별하여 3mm로 자르고 선별한 모낭 조직에 대해 대조군이 경우 약물을 처리하지 않고, 실험군의 경우 미녹시딜 10μM, 실시예 1의 에델바이스 추출물 50ppm, 100ppm을 처리하였다. 약물처리 후 3일, 7일, 11일, 14일 후 각각 길이 측정 및 사진촬영을 진행하였다. 그 결과를 도 4에 나타내었다.Hair follicles were isolated from the scalp and scalp tissue of a 55 year old male with William's E medium (L-glutamine (2 mM), insulin (10 µg / ml), hydrocortisone (40 ng / ml), antibiotics (1%), fungizon (1%). )). After 3 days of culture, the hair follicles were grown, cut to 3 mm, and the selected hair follicle tissues were treated with no drug in the control group, and the experimental group was treated with minoxidil 10 μM and the Edelweiss extract of Example 1 50 ppm and 100 ppm. After 3 days, 7 days, 11 days, and 14 days after drug treatment, length measurement and photographing were performed, respectively. The results are shown in FIG.
도 4에서 볼 수 있듯이, 모낭 기관에서 모발의 길이 증가에 있어서 50ppm의 에델바이스 추출물을 처리한 경우 양성 대조군인 미녹시딜과 비슷한 수준의 모발 성장 촉진 효과가 나타났다. 게다가 100ppm의 에델바이스 추출물을 처리한 경우에는 그 효과가 미녹시딜을 앞섰다. 이는 모두 통계학적으로 유의미한 것이다. 따라서 이를 통해 에델바이스 추출물은 모낭에서 모발의 길이 성장을 촉진하는 효과가 있음을 알 수 있다. As can be seen in Figure 4, when treated with 50ppm edelweiss extract in the hair length increase in hair follicle organs showed a hair growth promoting effect similar to the minoxidil positive control. Moreover, when 100ppm of edelweiss extract was treated, the effect was superior to minoxidil. All of these are statistically significant. Therefore, it can be seen that the edelweiss extract has an effect of promoting the length of hair growth in the hair follicles.
또한 모발이 모주기 중 성장기(anagen)에 있을 때 길이 성장이 일어나고, 퇴행기(catagen)로 전이되면 모발이 빠지기 시작한다. 에델바이스 처리군의 경우 처리 후 14일이 경과한 때에도 두 농도 모두에 있어서 미녹시딜 보다 생장기에 있는 모낭의 비율이 높았으며, 이는 퇴행기로 전이되는 모낭을 줄여 모발 성장이 일어나게 하는 효과가 있음을 나타낸다.In addition, the length of the growth occurs when the hair is in the anagen phase of the hair cycle, and the hair begins to fall out when it is transferred to the catagen. In the Edelweiss treatment group, even after 14 days of treatment, the ratio of hair follicles in the growing stage was higher than that of minoxidil at both concentrations, indicating an effect of reducing hair follicles that metastasize to hair growth.
[시험예 5] 에델바이스 추출물 내 지표 물질 함량 분석Test Example 5 Analysis of Indicator Material Content in Edelweiss Extract
에델바이스 추출물에 존재하는 화합물에는 클로로겐산, 루테올린, 아피게닌, 레온토포딕산 등이 알려져 있다. 본 지표 물질들은 고성능 액상 크로마토그래피 (HPLC, High performance liquid chromatography) 분석 방법으로 정성 및 정량 분석이 가능하다. 클로로겐산은 커피에 다량 포함되어있는 폴리페놀 화합물의 일종으로, 항산화 효과가 있는 것으로 알려져 있다. 에델바이스 추출물 내 지표 물질의 함량을 분석해보았을 때 클로겐산의 함량이 가장 높게 나타났기 때문에, 본 발명에서는 효소처리 추출 방법의 추출 효율을 분석하기 위해 클로로겐산의 함량 변화를 이용하였다.Chlorogenic acids, luteolin, apigenin, leontopodic acid and the like are known as compounds present in the edelweiss extract. The indicators can be qualitatively and quantitatively analyzed by high performance liquid chromatography (HPLC) analysis. Chlorogenic acid is a kind of polyphenolic compound contained in coffee in large quantities and is known to have an antioxidant effect. Since the content of the chlorogenic acid was the highest when the content of the indicator substance in the edelweiss extract was analyzed, the content of chlorogenic acid was used in the present invention to analyze the extraction efficiency of the enzyme treatment extraction method.
자세한 분석 방법은 다음과 같다. 실시예 1의 에델바이스 추출물과 실시예 2의 효소처리 에델바이스 추출물은 원액을 분석하고, 표준품으로 사용하는 클로로겐산은 50% 메탄올에 5μg/ml 농도로 녹여 사용하였다. 분석에 사용한 HPLC 기기는 Water사 Alliance 2695E model HPLC 이며, 검출기는 Water사의 PDA detector 2998 model이며, 칼럼은 Mightysil-RP18 (4.6 x 250, 5 um)이다. 표준품(standard)은 2,5,10 μg/mL로 조제하여 3 point calibration curve를 그려, 에델바이스 추출물 내 클로로겐산을 정량하였다.Detailed analysis method is as follows. The edelweiss extract of Example 1 and the enzyme treatment of the edelweiss extract of Example 2 were analyzed the stock solution, and chlorogenic acid used as a standard was dissolved in 50% methanol at a concentration of 5 g / ml. The HPLC instrument used in the analysis was a Water Alliance 2695E model HPLC, the detector was a PDA detector 2998 model from Water, and the column was Mightysil-RP18 (4.6 x 250, 5 um). Standard was prepared at 2,5,10 μg / mL to draw a 3-point calibration curve to quantify the chlorogenic acid in the edelweiss extract.
추출물 10μl를 주입하고 분석 용매는 A(20 mM KH2PO4(pH 2.5)) / B(ACN)를 다음과 같은 gradient로 흘려주었다. 유량은 1 mL/min이다.10 μl of the extract was injected and the analytical solvent was flowed A (20 mM KH 2 PO 4 (pH 2.5)) / B (ACN) into the following gradient. The flow rate is 1 mL / min.
표 1
time(min) A B
0 96 4
1 96 4
60 55 45
65 40 60
70 40 60
75 96 4
82 96 4
Table 1
time (min) A B
0 96 4
One 96 4
60 55 45
65 40 60
70 40 60
75 96 4
82 96 4
클로로겐산의 retention time은 17분이며 검출 파장은 326nm이다. The retention time of chlorogenic acid is 17 minutes and the detection wavelength is 326 nm.
도 7에서와 같이, 셀룰라아제 효소 처리 후 에델바이스 추출물 내 클로로겐산의 양이 처리하기 전에 비해 급격히 증가한 것을 볼 수 있었다. 즉, 셀룰라아제 효소를 처리함으로써 에델바이스 세포벽이 분해되면서 식물 내부의 지표 성분의 추출 효율이 증가한 것을 알 수 있었다. 따라서 본 효소처리를 포함하는 추출법으로 얻은 효소처리 에델바이스 추출물은 효소처리를 하지 않은 추출물에 비해 유효 성분을 다량 함유하고 있을 것임을 알 수 있었다. As shown in Figure 7, after the cellulase enzyme treatment it can be seen that the amount of chlorogenic acid in the edelweiss extract increased significantly compared to before treatment. In other words, by treating the cellulase enzyme, as the Edelweiss cell wall was decomposed, it was found that the extraction efficiency of the indicator component in the plant was increased. Therefore, it can be seen that the enzyme-treated edelweiss extract obtained by the extraction method including the present enzyme treatment may contain a large amount of the active ingredient compared to the extract without the enzyme treatment.
[시험예 6] 에델바이스 지표 성분의 항산화 효과 평가Test Example 6 Evaluation of Antioxidant Effect of Edelweiss Index Component
에델바이스 지표 성분인 클로로겐산의 항산화 효과를 평가하기 위하여 DPPH 항산화 평가법을 사용하였다. 체내에서 일어나는 산화 반응은 주로 자유 라디칼에 의해 일어나고, 이러한 작용은 세포의 노화 및 암 발생을 초래하는 것으로 알려져있다. 따라서 체내의 자유 라디칼 생성 억제는 결국 체내 항산화, 항노화와 연관될 수 있으며, 이러한 항산화 효과는 체내의 자유 라디칼을 대상으로 실험하기 어렵기 때문에 DPPH(2,2-diphenyl-1-picrylhydrazyl) 라디칼을 보편적으로 사용하고 있다. DPPH 라디칼은 짙은 보라색을 띠고 있는데 항산화 효능 물질과 만나 반응하면 옅은 노란색으로 바뀌며 517nm 파장에서 흡광도를 측정하여 항산화능을 평가한다. 항산화능이 높은 물질일수록 색이 옅은 노란색을 띠면서 흡광도가 낮아진다.The DPPH antioxidant assay was used to evaluate the antioxidant effect of chlorogenic acid, an edelweiss index component. Oxidation reactions occurring in the body are mainly caused by free radicals, and this action is known to lead to the aging of cells and the development of cancer. Therefore, inhibition of free radical production in the body may eventually be associated with antioxidant and anti-aging in the body, and since this antioxidant effect is difficult to experiment with free radicals in the body, DPPH (2,2-diphenyl-1-picrylhydrazyl) radicals may be It is used universally. DPPH radicals have a deep purple color. When they react with antioxidant compounds, they turn to pale yellow color and measure their absorbance at 517 nm. Higher antioxidants have a lighter yellow color and lower absorbance.
본 실험에서는 96웰 플레이트에 0.1mM DPPH용액을 넣은 후 양성대조군인 비타민 C와 클로로겐산을 각각 반응시켜 517nm에서 흡광도를 측정하였다. 이 때, 용매로는 물을 사용하였고, 비타민 C는 25, 50, 100μg/ml의 양으로 처리하였으며, 클로로겐산은 1.25, 2.5, 5, 10ppm의 양으로 처리하였다. 반응은 37℃ 배양기에서 30분간 진행하였다. 결과는 도 8에 나타내었다.In this experiment, 0.1mM DPPH solution was added to a 96-well plate, and the absorbance was measured at 517 nm by reacting the positive control vitamin C and chlorogenic acid, respectively. At this time, water was used as a solvent, vitamin C was treated in the amount of 25, 50, 100μg / ml, chlorogenic acid was treated in the amount of 1.25, 2.5, 5, 10ppm. The reaction was carried out for 30 minutes in a 37 ℃ incubator. The results are shown in FIG.
도 8에서 볼 수 있는 바와 같이 클로로겐산을 처리한 경우 농도 의존적으로 항산화 효과를 보이는 것을 확인하였다. 이를 통하여, 클로로겐의 함량이 증가한 효소처리 에델바이스 추출물의 경우 처리 전에 비해 항산화 효과가 증가할 수 있음을 알 수 있다.As can be seen in Figure 8, when treated with chlorogenic acid was confirmed to show an antioxidant effect in a concentration-dependent. Through this, it can be seen that in the case of the enzyme treatment Edelweiss extract with an increased content of chlorogen, the antioxidant effect can be increased compared to before the treatment.
본 발명의 일측면에 따른 조성물의 제형예를 아래에서 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Examples of the formulation of the composition according to one aspect of the present invention will be described below, but can be applied to various other formulations, which are intended to explain in detail only, not intended to limit the invention.
[제형예 1] 연고의 제조Formulation Example 1 Preparation of Ointment
아래 표에 기재된 조성으로 통상의 방법에 따라 연고를 제조한다.Ointments are prepared according to conventional methods with the compositions described in the table below.
표 2
성분 함량(중량%)
정제수 잔량
글리세린 8.0
부틸렌그리콜 4.0
유동파라핀 15.0
베타글루칸 7.0
카보머 0.1
에델바이스 추출물 5.0
카프릴릭 카프릭 트리글리세라이드 3.0
스쿠알렌 1.0
세테아릴 글루코사이드 1.5
소르비탄 스테아레이트 0.4
스테아릴 알코올 1.0
방부제 적량
적량
색소 적량
밀랍 4.1
TABLE 2
ingredient Content (% by weight)
Purified water Remaining amount
glycerin 8.0
Butylene glycol 4.0
Liquid paraffin 15.0
Beta Glucan 7.0
Carbomer 0.1
Edelweiss extract 5.0
Caprylic Capric Triglycerides 3.0
Squalene 1.0
Cetearyl Glucoside 1.5
Sorbitan stearate 0.4
Stearyl alcohol 1.0
antiseptic Quantity
incense Quantity
Pigment Quantity
beeswax 4.1
[제형예 2] 헤어 로션의 제조Formulation Example 2 Preparation of Hair Lotion
아래 표에 기재된 조성으로 통상의 방법에 따라 헤어 로션을 제조한다.A hair lotion is prepared according to a conventional method with the composition described in the table below.
표 3
성분 함량(중량%)
정제수 잔량
글리세린 3.0
부틸렌그리콜 3.0
유동파라핀 7.0
베타글루칸 7.0
카보머 0.1
에델바이스 추출물 2.0
카프릴릭 카프릭 트리글리세라이드 3.0
스쿠알렌 5.0
세테아릴 그루코사이드 1.5
소르비탄 스테아레이트 0.4
폴리솔베이트 1.2
방부제 적량
적량
색소 적량
트리에탄올 아민 0.1
TABLE 3
ingredient Content (% by weight)
Purified water Remaining amount
glycerin 3.0
Butylene glycol 3.0
Liquid paraffin 7.0
Beta Glucan 7.0
Carbomer 0.1
Edelweiss extract 2.0
Caprylic Capric Triglycerides 3.0
Squalene 5.0
Cetearyl Glucoside 1.5
Sorbitan stearate 0.4
Polysorbate 1.2
antiseptic Quantity
incense Quantity
Pigment Quantity
Triethanol amine 0.1
[제형예 3] 크림의 제조Formulation Example 3 Preparation of Cream
아래 표에 기재된 조성으로 통상의 방법에 따라 크림을 제조한다.A cream is prepared according to a conventional method with the composition described in the table below.
표 4
성분 함량(중량%)
정제수 잔량
글리세린 8.0
부틸렌그리콜 4.0
유동파라핀 45.0
베타글루칸 7.0
카보머 0.1
에델바이스 추출물 1.5
카프릴릭 카프릭 트리글리세라이드 3.0
밀랍 4.0
세테아릴 글루코사이드 1.5
세스퀴 올레인산 소르비탄 0.9
바세린 3.0
방부제 적량
적량
색소 적량
트리에탄올 아민 0.1
Table 4
ingredient Content (% by weight)
Purified water Remaining amount
glycerin 8.0
Butylene glycol 4.0
Liquid paraffin 45.0
Beta Glucan 7.0
Carbomer 0.1
Edelweiss extract 1.5
Caprylic Capric Triglycerides 3.0
beeswax 4.0
Cetearyl Glucoside 1.5
Sesqui oleic acid sorbitan 0.9
Vaseline 3.0
antiseptic Quantity
incense Quantity
Pigment Quantity
Triethanol amine 0.1
[제형예 4] 정제Formulation Example 4 Tablets
에델바이스 추출물 10 mg, 대두 추출물 50 mg, 포도당 100 mg, 홍삼 추출물 50 mg, 전분 96 mg 및 마그네슘 스테아레이트 4 mg을 혼합하고 에탄올을 첨가하여 과립을 형성한 후 건조하고 정제로 타정한다.10 mg of edelweiss extract, 50 mg of soybean extract, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch and 4 mg of magnesium stearate are mixed and granules are formed by adding ethanol, dried and tableted.
[제형예 5] 건강 음료Formulation Example 5 Healthy Drink
에델바이스 추출물...................... 100 ㎎ Edelweiss extract ............ 100 mg
구연산................................ 1000 ㎎ Citric Acid ................................... 1000 mg
올리고당................................ 100 g Oligosaccharide ......................... 100 g
타우린.................................... 1 g Taurine .................................... 1 g
정제수............ ...................... 적량 Purified water ..................
통상의 건강 음료 제조 방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균한다.The above ingredients are mixed according to a conventional method for preparing a health beverage, then stirred and heated at 85 ° C. for about 1 hour, and then the resulting solution is filtered and sterilized.

Claims (17)

  1. 에델바이스 추출물을 유효성분으로 포함하는 피부 재생 촉진제. Skin regeneration accelerator comprising edelweiss extract as an active ingredient.
  2. 에델바이스 추출물을 유효성분으로 포함하는 모발 성장 촉진제.Hair growth promoter comprising an edelweiss extract as an active ingredient.
  3. 제 1항에 있어서, 에델바이스 추출물은 효소처리 에델바이스 추출물인 촉진제.The promoter of claim 1, wherein the edelweiss extract is an enzyme treated edelweiss extract.
  4. 제 2항에 있어서, 에델바이스 추출물은 효소처리 에델바이스 추출물인 촉진제.The promoter of claim 2, wherein the edelweiss extract is an enzyme treated edelweiss extract.
  5. 제3항 또는 제4항에 있어서, 상기 효소는 세포벽 분해효소인, 촉진제. The promoter according to claim 3 or 4, wherein the enzyme is a cell wall degrading enzyme.
  6. 제3항 또는 제4항에 있어서, 상기 효소는 셀룰라아제 (cellulase), 크실라나아제 (xylanase) 및 아라비노푸라노시다아제 (arabinofuranosidase)로 이루어진 군에서 선택되는, 촉진제.The promoter according to claim 3 or 4, wherein the enzyme is selected from the group consisting of cellulase, xylanase and arabinofuranosidase.
  7. 제3항 또는 제4항에 있어서, 상기 추출물은 효소를 에델바이스 총중량에 대하여 0.001 내지 1중량%로 첨가하여 얻어지는, 촉진제.The promoter according to claim 3 or 4, wherein the extract is obtained by adding an enzyme in an amount of 0.001 to 1% by weight based on the total weight of edelweiss.
  8. 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 촉진제는 에델바이스 추출물 또는 효소 처리 에델바이스의 추출물을 촉진제 총 중량에 대하여 0.01 내지 10중량%로 포함하는, 촉진제.The promoter according to any one of claims 1 to 4, wherein the promoter comprises an edelweiss extract or an extract of the enzyme treated edelweiss in an amount of 0.01 to 10% by weight based on the total weight of the promoter.
  9. 제1항 또는 제3항에 있어서, 상기 촉진제는 피부 상처를 치유하는, 피부 재생 촉진제.The skin regeneration accelerator according to claim 1 or 3, wherein the accelerator heals a skin wound.
  10. 제2항 또는 제 4항에 있어서, 상기 촉진제는 탈모를 방지하거나 또는 양모를 촉진하는, 모발 성장 촉진제.The hair growth promoter according to claim 2 or 4, wherein the accelerator prevents hair loss or promotes wool.
  11. 제3항 또는 제 4항에 있어서, 상기 촉진제는 항산화능을 가지는, 촉진제.The promoter according to claim 3 or 4, wherein the promoter has an antioxidant capacity.
  12. 제3항 또는 제4항에 있어서, 상기 에델바이스 추출물은 클로로겐산 (chlorogenic acid)을 전체 추출물 중량에 대하여, 6ppm이상 포함하는, 촉진제.The accelerator according to claim 3 or 4, wherein the edelweiss extract contains chlorogenic acid, based on the total extract weight, of 6 ppm or more.
  13. 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 에델바이스는 레온토포이움 속 (Leontopoium sp.)인, 촉진제.5. The promoter according to claim 1, wherein the edelweiss is Leontopoium sp.
  14. 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 에델바이스는 레온토포이움 알피늄(Leontopoium alpinum)인, 촉진제.5. The promoter of claim 1, wherein the edelweiss is Leontopoium alpinum . 6.
  15. 제 1 항 내지 제4항 중 어느 한 항에 있어서,The method according to any one of claims 1 to 4,
    촉진제는 세포에서 윈트 신호(Wnt signal)를 활성화하는 촉진제.A promoter is a promoter that activates a Wnt signal in a cell.
  16. 제 1 항 내지 제4항 중 어느 한 항에 따른 촉진제를 포함하는 화장료 조성물.Cosmetic composition containing an accelerator according to any one of claims 1 to 4.
  17. 제 1 항 내지 제4항 중 어느 한 항에 따른 촉진제를 포함하는 약학 조성물.A pharmaceutical composition comprising an accelerator according to any one of claims 1 to 4.
PCT/KR2013/004833 2012-05-31 2013-05-31 Skin regeneration and hair growth promoter containing edelweiss extract WO2013180526A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120058027 2012-05-31
KR10-2012-0058027 2012-05-31

Publications (1)

Publication Number Publication Date
WO2013180526A1 true WO2013180526A1 (en) 2013-12-05

Family

ID=49673646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/004833 WO2013180526A1 (en) 2012-05-31 2013-05-31 Skin regeneration and hair growth promoter containing edelweiss extract

Country Status (2)

Country Link
KR (2) KR20130135165A (en)
WO (1) WO2013180526A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2810697A1 (en) * 2013-06-05 2014-12-10 Henkel AG&Co. KGAA Hair-growth agent containing Leontopodium extract
EP2873440A1 (en) * 2013-11-19 2015-05-20 DSM IP Assets B.V. Use of an edelweiss extract in hair care for stimulating hair growth
KR20150076475A (en) 2013-12-27 2015-07-07 코웨이 주식회사 Complex having dedifferentiated plant protoplast inserted active material, preparation method thereof, and cosmetic composition comprising the same
KR20160068190A (en) 2014-12-05 2016-06-15 코웨이 주식회사 Stabilization Method of Dedifferentiated Plant Protoplast Complex With Active Material Insertion
KR20160106268A (en) 2015-03-02 2016-09-12 코웨이 주식회사 Microcapsules Containing Dedifferentiated Plant Protoplast Complex With Active Material Insertion and Cosmetic Composition Comprising the Microcapsules
EP3328406A4 (en) * 2015-07-27 2019-05-01 MOREIRA, Nivaldo José Mulateiro-derived compositions and use thereof for preventing hair loss and promoting hair growth
CN117205129A (en) * 2023-11-08 2023-12-12 北京尧景基因技术有限公司 Extraction method of alpine leontopodium herb vesicles and application of alpine leontopodium herb vesicles in preparation of skin cell collagen regeneration and repair products

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102296494B1 (en) 2020-09-29 2021-09-01 주식회사 엑소코바이오 New composition comprising exosomes derived from Edelweiss as an active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082117A1 (en) * 1999-12-23 2003-05-01 Richard Martin Genus leontopodium plant extract and compositions containing same
KR100512690B1 (en) * 2002-11-29 2005-09-07 나드리화장품주식회사 Cosmetic composition containing bletilla striata and leontopodium alpinum extract
WO2011089161A1 (en) * 2010-01-19 2011-07-28 Medizinische Universität Wien Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU83173A1 (en) * 1981-02-27 1981-06-05 Oreal NOVEL COSMETIC COMPOSITIONS FOR THE TREATMENT OF HAIR AND SKIN CONTAINING POWDER RESULTING FROM THE SPRAYING OF AT LEAST ONE PLANT AND A COHESION AGENT
JP2009084212A (en) 2007-09-28 2009-04-23 Naris Cosmetics Co Ltd Involucrin production promoter

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082117A1 (en) * 1999-12-23 2003-05-01 Richard Martin Genus leontopodium plant extract and compositions containing same
KR100512690B1 (en) * 2002-11-29 2005-09-07 나드리화장품주식회사 Cosmetic composition containing bletilla striata and leontopodium alpinum extract
WO2011089161A1 (en) * 2010-01-19 2011-07-28 Medizinische Universität Wien Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHWAIGER, STEFAN ET AL.: "Leontopodic acid-a novel highly substituted glucaric acid derivative from Edelweiss (Leontopodium alpinum Cass.) and its antioxidative and DNA protecting properties.", TETRAHEDRON, vol. 61, no. 19, 2005, pages 4621 - 4630 *
YAN, XU ET AL.: "Extraction study of berberine from cortex phellodendri by ultrasonic wave-cellulase.", LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH., vol. 6, 2007 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2810697A1 (en) * 2013-06-05 2014-12-10 Henkel AG&Co. KGAA Hair-growth agent containing Leontopodium extract
EP2873440A1 (en) * 2013-11-19 2015-05-20 DSM IP Assets B.V. Use of an edelweiss extract in hair care for stimulating hair growth
KR20150076475A (en) 2013-12-27 2015-07-07 코웨이 주식회사 Complex having dedifferentiated plant protoplast inserted active material, preparation method thereof, and cosmetic composition comprising the same
KR20160068190A (en) 2014-12-05 2016-06-15 코웨이 주식회사 Stabilization Method of Dedifferentiated Plant Protoplast Complex With Active Material Insertion
KR20160106268A (en) 2015-03-02 2016-09-12 코웨이 주식회사 Microcapsules Containing Dedifferentiated Plant Protoplast Complex With Active Material Insertion and Cosmetic Composition Comprising the Microcapsules
EP3328406A4 (en) * 2015-07-27 2019-05-01 MOREIRA, Nivaldo José Mulateiro-derived compositions and use thereof for preventing hair loss and promoting hair growth
CN117205129A (en) * 2023-11-08 2023-12-12 北京尧景基因技术有限公司 Extraction method of alpine leontopodium herb vesicles and application of alpine leontopodium herb vesicles in preparation of skin cell collagen regeneration and repair products
CN117205129B (en) * 2023-11-08 2024-02-23 北京尧景基因技术有限公司 Extraction method of alpine leontopodium herb vesicles and application of alpine leontopodium herb vesicles in preparation of skin cell collagen regeneration and repair products

Also Published As

Publication number Publication date
KR20130135165A (en) 2013-12-10
KR102022538B1 (en) 2019-09-18
KR20130135164A (en) 2013-12-10

Similar Documents

Publication Publication Date Title
WO2013180526A1 (en) Skin regeneration and hair growth promoter containing edelweiss extract
KR102257524B1 (en) Cosmetic composition for improving skin condition Centella Asiatica―derived exsome having skin calming and regeneration
KR101885501B1 (en) Functional composition comprising deer antlers derived stem cell culture medium
KR20180047952A (en) Functional composition comprising deer antlers derived stem cell culture medium
KR20160069488A (en) Composition for preventing hair loss and promoting hair growth comprising the effective amount of bee venom
WO2017217695A1 (en) Composition comprising alpha-garcinia mangostana, beta-garcinia mangostana, gamma-garcinia mangostana, or gartanin compound as effective ingredient for improving skin wrinkle or for moisturizing skin
KR101902425B1 (en) Agent for improving regeneration comprising Gardenia jasminodes extracts
KR101484033B1 (en) Composition for preventing hair loss or promoting hair growth comprising an extract of shell Arachis hypogaea Linne
KR101541470B1 (en) Composition for preventing hair loss or promoting hair growth comprising Ginsenoside F2
WO2020101414A1 (en) Composition for promoting skin regeneration and hair growth, containing apigenin
WO2020138834A1 (en) Composition for preventing or treating skin diseases comprising bridalwreath spirea
WO2020127888A2 (en) Urban darkening skin composition and formulation
KR20140091376A (en) Composition for preventing hair loss or promoting hair growth comprising an extract of Chrysanthemum morifolium
KR101167510B1 (en) Composition for preventing hair loss or promoting hair growth comprising an saponin biotransformant of Ginseng
WO2021215882A1 (en) Composition for preventing hair loss or promoting hair growth comprising camellia pericarp extract as active ingredient
WO2019225891A1 (en) Skin anti-aging composition containing irilin b
KR101438332B1 (en) Composition for preventing hair loss or promoting hair growth comprising forsythiaside-A
JP4197194B2 (en) Oral administration agent for intercellular adhesion suppression
WO2016056780A1 (en) Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract
WO2019132217A1 (en) Cosmetic composition comprising styphnolobium japonicum fruit fermented solution or extract liquid thereof as effective ingredient for reducing skin wrinkle and preparation method therefor
WO2015005700A1 (en) Composition for promoting hair sprouting and hair growth
KR102105672B1 (en) Cosmetic Composition for comprising longanae arillus extracts
KR101297641B1 (en) Composition Comprising Extracts of Rubus coreanum Miquel
KR20210131680A (en) Composition for preventing hair loss or promoting hair growth comprising Pectin
KR20190020539A (en) A composition for improving alopecia containing novel compounds isolated from chestnut bur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13797029

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06/05/2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13797029

Country of ref document: EP

Kind code of ref document: A1